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Abstract
Signal transduction and stage-specific gene expression are essential
components of Plasmodium falciparum development. In this study, the putative
phosphatase PF13_0027 is investigated as a critical component of
intraerythrocytic development contributing to maturation of the late trophozoite.
This putative phosphatase was identified during the course of a large-scale
insertional mutagenesis project by insertion of the piggyBac (pB) element,
containing a human dihydrofolate reductase (hDHFR) drug selection cassette
into the open reading frame (ORF) preventing expression and attenuating
parasite development. PF13_0027 codes for a protein with a rhodanese (RHD)
and dual specificity phosphatase (DUSP) in a tandem arrangement typically
identified with mitogen-activated protein kinase (MAPK) phosphatases (MKP).
Despite numerous INDELs, the tertiary structure is conserved when compared to
the solved structures of MKP homologs. The expression profile reveals
transcripts at all stages of the blood cycle with a highest relative abundance in
the late trophozoite. Restoration of the phenotype was achieved through genetic
complementation using the complete PF13_0027 open reading frame (ORF)
under the control of its endogenous promoter. A homology model of PF13_0027
was developed for structural analysis and evaluated using in silico highix

throughput screening (HTS) to identify antimalarial compounds with predicted
affinity to the active site and used to challenge parasites in vitro. This study
reveals that PF13_0027 is a vital component of asexual development and a
potential target for a new class of antimalarial compounds targeting
phosphorylation pathways in P. falciparum. Discovery of the functional role of
this unknown ORF provides additional insight into the importance of MAPK
signaling in P. falciparum.

x

Chapter 1: Background and Introduction
Malaria: A Global View
Malaria is a devastating disease responsible for approximately 800,000
deaths and 250 million clinical illnesses annually [10-12]. Clinical disease
resulting from malaria is caused by cyclic intraerythrocytic development of the
parasites in the blood [13-15]. This cycle of development is highly dependent on
a progressive pattern of gene expression, and it is widely believed that the
observed cyclical pattern of malaria parasites is ‘hard wired’ into the genome in
contrast with most eukaryotic organisms that can variably regulate cell cycle
development [16-20]. The protozoan parasites responsible for this disease have
a history stretching back as far as 30 million years and have been mentioned
throughout recorded history [21-25]. These parasites belong to the phylum
apicomplexa and there are five species of Plasmodium known to infect humans;
P. falciparum, P, vivax, P. malariae, P. ovale, and P. knowlesi [26, 27]. Of these
five species, P. falciparum is the most severe and thought to have originated in
Africa about 10 000 years ago [26-34]. To overcome the chronic and widespread
nature of this disease there is an urgent need for vaccines to prevent infection
and new drugs for prophylaxis and curative treatments [29, 35, 36]. Currently,
many of the antimalarial drugs used to control malaria are rapidly losing their
1

efficacy due to the adaptations of the parasite and the common chemical nature
and targets of many current drugs [20, 37-40]. In the effort to develop new
therapies, studies interpreting the genome have been vital to the understanding
of Plasmodium biology [10]. The completed sequencing of the P. falciparum
genome in 2002 has contributed a lot of vital information to this effort, but
converting that information into new therapies has been slow due to the high
quantity of encoded hypothetical genes and unknown ORFs [10].
Forward Genetics with piggyBac Transposon-mediated Mutagenesis
Due to the lack of robust molecular genetic tools for manipulating the
Plasmodium genome, translation of the genomic information to chemotherapeutic
strategies has been an arduous process [41-43]. Of all the developmental
stages in P. falciparum, the blood stages are the only stage that can be
effectively cultured in vitro [44-46]. This stage is also the only one amenable to
transfection with exogenous DNA [44, 47]. To investigate the Plasmodium
genome, our lab uses random insertional mutagenesis with the transposable
element piggyBac (pB) [9, 48]. Through this method, we have been able to
identify genes important for the development of P. falciparum through individual
gene knockouts followed by phenotypic characterization [9]. One of the main
advantages to this method is that it has proven to be quicker and more efficient
than homologous recombination, which is a lengthy process (6-12 months)
requiring individual targeting plasmids for each recombination [9, 45, 46, 49-52].
With the pB mutagenesis method, we have been able to knock out several genes
2

in the genome of P. falciparum, providing new avenues for in depth
characterization of the genome (Figure 1.1). Throughout this process, the
putative phosphatase PF13_0027 was identified as important to intraerythrocytic
development. Further investigation revealed that the structure of PF13_0027 is
conserved with MKPs and may provide insight into a more complex underlying
signal transduction pathway. This novel putative phosphatase could potentially
develop much needed avenues for future antimalarial drug design.
Global Impact of Malaria
Malaria has been a huge problem in endemic regions throughout history;
however, in the past century progress has been made successfully reducing the
incidence of malaria in some endemic regions. In recent times major advances
controlling malaria have occurred in Sub-Saharan Africa, which experiences the
greatest burden due to malaria. The burden of malaria in this region is mainly
fueled by the prevalence of the vector Anopheles gambiae, a long lived mosquito
that feeds predominantly on humans and has been effective in transmitting
malaria from person to person [53]. The most common cause of severe malaria,
and the cause of most cases in Africa are the result of P. falciparum (Figure 1.2)
infection, while P. vivax (Figure 1.3) is the most common cause of malaria
outside of Africa [54-58].
Fortunately some progress has been made in controlling the effects of
malaria in endemic regions. Reported malaria cases in 2000 to 2010 decreased
more the 50% in 43 of the 99 countries with ongoing transmission. Downward
3

trends of 25-50% were observed in 8 other countries while global incidence of
malaria was reduced by 17% since 2000 with mortality rates reduced by 26%
[59]. According to the World Malaria Report released by the World Health
Organization (WHO) in 2011, this target fell short of the international goal of 50%;
however, it is still a major achievement. Conversely, the global reach of malaria
still threatens approximately 40% of the earth’s population in tropical and
subtropical regions [33, 60, 61]. In Sub-Saharan Africa, this disease is both a
cause and consequence of poverty, having an economic impact that slows
growth by 1.3% annually, translating into a gross domestic product cost of $12
billion [38, 62, 63]. Most cases of the most severe form of malaria, P falciparum,
are confined to the continent of Africa accounting for approximately 90% of all
deaths [53, 59]. Globally 86% of all malaria cases are children under the age of
five [38, 64].
To understand the larger picture of malaria’s effect within endemic regions
it is necessary to have an effective method in place to track and record its
impact. Tracking and measuring malaria prevalence is an arduous process
which is undertaken utilizing a variety of methods. These approaches have both
advantages and disadvantages, but they provide critical information supporting
strategies aimed at controlling and eradicating malaria. Four of the methods
used for measuring malaria transmission are; entomological inoculation rate
(EIR), parasite rate (PR), annual parasite index (API), and spleen rate (SR). The
EIR is a measure of infectious bites per unit time (usually one year), and is
considered a direct reflection of the vector control and gametocytocidal drugs
4

[65, 66]. One of the drawbacks to this method is that there are not any standard
protocols, so there is variability in the methodologies, and there are few
specialists trained in the technique. It was found that in some cases false
positives from enzyme-linked immunosorbent assay (ELISA) techniques
detecting circumsporozoite protein (CSP) could lead to an overestimation of EIR
[67]. The PR looks at the proportion of the population carrying asexual stage
parasites in the blood and can assess the gametocyte rates by age group. An
advantage of this method is that it provides a direct reflection of the effectiveness
of inoculations, immunity and treatment in humans. Some of the challenges
imposed by this method are that the results can be affected by environmental
control factors and the accuracy depends on the technical efforts of the
microscopy, which can be inconsistent when comparing a variety of regions [68,
69]. The API looks at the number of parasite infections within a defined
geographical area (typically 1000 persons per year). This method is considered
a direct reflection of all the prevention and control effects on humans, but
depends on active case detection data that often can be poor. SR looks at the
proportion of children 2-9 year of age that have a palpable spleen. This is a noninvasive way of measuring the impact of malaria on the spleen. However, there
are many causes of splenomegaly that complicate interpretation. Additionally,
rapid changes in point prevalence, and variability in examiner techniques, has
also been an issue contributing to inconsistencies in this method of reporting
[70].

5

Pathogenesis
Manifestation of malaria’s clinical symptoms can range from mild to severe
and even death, although it is curable if diagnosed and treated promptly. Most
infections of adults living in endemic areas are clinically silent due to adaptive
immunity, that is able to prevent disease, while the more clinically overt cases
occur in non-immune individuals [71]. Two major factors influencing the
progression of disease is the age and immune status of the infected individual.
In the endemic regions of Africa, the major burden of malaria is in children under
the age of five and pregnant women [12, 38]. Due to this threat, the fight against
malaria has employed a multifaceted approach to reduce infection in these at-risk
populations.
The pathogenesis of malaria is a complicated process modulated by both
parasite and host factors allowing it to successfully propagate in the various
environments of their hosts. One such mechanism is the ability to express
variant surface antigens such as P. falciparum erythrocyte membrane protein 1
(PfEMP-1) that allows the infected red blood cells (RBCs) to bind to vascular
receptors preventing splenic clearance [72, 73]. The challenge posed by
immune recognition via this surface protein is circumvented by antigenic variation
[38, 71, 74]. However, development of cross-reactive antibodies to
subpopulations of variant antigens has been found to produce semi-protective
immunity [74, 75]. Unfortunately multiple gaps still remain in the most effective
strategies leaving solutions to this challenge out of our reach [76].

6

During development in RBCs several toxic byproducts of metabolism
including hemozoin, accumulate in the infected cell. When the RBC lyses to
release invasive merozoites, toxic byproducts stimulate macrophages to release
cytokines producing acute inflammatory responses [77]. Typically, these
infections are divided into two categories; uncomplicated and complicated (or
severe) malaria. Uncomplicated cases commonly present a combination of
fever, chills, sweats, headaches, nausea, body aches and general malaise [13,
14]. These symptoms can sometimes be associated with other illnesses, such
as a common cold or influenza, however when recognized as malaria, residents
in areas with frequent malaria infection tend to seek diagnostic confirmation or
treat themselves [38, 78]. Diagnosis depends on the observation of parasites in
the blood by microscopy, while other diagnostic observations may include a
decrease in blood platelets or elevation in bilirubin and aminotransferases [77].
More serious symptoms can occur in severe malaria which is accompanied by
organ failures and abnormalities in the patient’s blood and metabolism [79, 80].
Additionally, cerebral malaria and anemia are common occurrences as well as
low blood pressure, respiratory acidosis, and hypoglycemia [38, 74]. Recovery
from infections of P. vivax and P. ovale are sometimes followed by relapses due
to hypnozoites that can lay dormant in the liver for several weeks, months, or
even years [31, 81].

7

Plasmodium Life Cycle
The life cycle of Plasmodium depends on the infection of two distinct
hosts, a mosquito and a vertebrate (Figure 1.4). Asexual development in the
vertebrate host is comprised of an initial single round of exo-erythrocytic
schizogony in infected liver hepatocytes followed by potentially unlimited rounds
of intraerythrocytic schizogony. The intraerythrocytic stage of development (48
hour cycle) is the underlying cause of malaria. A product of intraerythrocytic
development is macro- and microgametocytes, which are ingested by mosquitos
when obtaining a blood meal.
Mosquito (Definitive Host)
Transmission of the malaria parasite from person to person occurs
through the bite of the female Anopheles mosquito. There are approximately
3500 species of mosquitos, of which, 430 are Anopheles [77]. Their geographic
range covers most global regions with the exception of the Antarctic (Figure 1.5)
[82]. Of the known Anopheles, 40 to 50 of these species are capable of
transmitting malaria and the ability of a given species to transmit malaria is
dependent on the region and environment. Since their range is not limited to
endemic regions, and includes areas where malaria has been eliminated, there is
always a looming risk of re-introduction [83]. Efforts have been made to
understand the behavior of mosquitos in an attempt to develop deeper insights
into the methods of malaria transmission. Some key factors that facilitate
mosquito transmission are the choice of host, life span, and susceptibility to
8

Plasmodium. Female mosquitos have a life span that can extend up to a month
while the males will live for approximately one week. Both male and female
mosquitos feed on nectar as an energy source, however, only the female
requires blood for the production of eggs [77]. Following ingestion of
gametocytes, the process of sporogony is activated by a combination of a 5 ºC
drop in temperature and the gametocyte activating factor xanthurenic acid which
stimulates the final maturation of the gametocytes to form gametes [84]. This
process is followed by fusion of the gametes to form a motile oökinete that
travels by intracellular migration through the midgut epithelium towards the BL.
The oökinete differentiates to an oöcyst and matures for approximately 10-15
days before releasing thousands of sporozoites. The sporozoites then migrate to
the salivary glands and are injected into the vertebrate host when the mosquito
feeds.
Human (Intermediate Host)
Humans become infected when mosquitos feed, injecting sporozoites into
skin around the bite area. During the feeding process, a single infected mosquito
can inject anywhere from 1-1297 sporozoites, although infection can occur with
as few as five [85, 86]. Sporozoites can remain in the skin for several hours
before migrating out into the blood vessels. Additionally up to 20% of the
sporozoite inoculum can enter the lymphatic system [87, 88]. Upon entering the
blood vessels, some sporozoites eventually arrive at the liver where they traverse
Küpffer cells prior to invading hepatocytes [14]. Development in the liver
9

hepatocytes produces large packages of merozoites (merosomes), which are
released from the liver into the bloodstream [14, 89]. Each merozoite invades a
RBC where they produce several invasive merozoites [13, 90, 91]. Lysis of the
RBC releases the merozoites that invade more uninfected RBCs. Continuation
of this cyclical process in the blood results in the fever and chills commonly
associated with malaria. In a process branching from this cycle, some of the
merozoites develop into gametocytes which are the stage ingested by the
mosquito during blood feeding.
Antimalarials
Over the years, numerous effective antimalarial drugs have been
developed, however these efforts have been threatened by emerging resistance.
With the decreasing effectiveness of some of the more common frontline drugs
such as chloroquine, atovaquone, sulfadoxine-pyrimethamine and mefloquine,
the effort to develop new drugs has been intensified [36, 40, 92-98].
Furthermore, recent emergence of artemisinin resistance has increased the
urgency of this effort [36, 40, 99, 100]. Notably, resistance to a certain
compound is manifest throughout the entire chemotype class, so efforts cannot
simply focus on modifying current drugs but rather aim to find new
pharmacophores as platforms for new malaria therapy [100-102].
Endoperoxides
The endoperoxides are comprised of artemisinin and its derivatives.
Artemisinin is extracted from the annual wormwood Artemisia annua and has
10

been used in traditional Chinese medicine for more than 2000 years in the
treatment of febrile illnesses [40]. Since its introduction and use in several
African and Asian countries the burden of malaria has successfully been
reduced. Use of these drugs as artemisinin combination therapies (ACTs),
combining two or more antimalarials with different modes of action together, is
encouraged due to the potential emergence of drug resistance in areas of high
drug pressure [103]. Though a consensus has not been reached on the
mechanism of action, the antimalarial activity is thought to arise from the
peroxide bridge present in all the compounds [64, 104]. Endoperoxides have
been safe and active against a wide range of Plasmodium stages including
immature and developing gametocytes [105].
Derivatives that are used in combination therapies vary in their activity
profiles and have been utilized in diverse situations. Dihydroartemisinin (DHA)
has been used in combination with piperaquine, and registered for distribution
under the name Artekin™ [93]. It has been very effective and was evaluated in
clinical trials in Thailand, Vietnam, Cambodia, and China [106]. Derivatives of
DHA are artemether, artesunate and artemotil. These derivatives have better
biavailability than artemisinin and are used as a once or twice a day dosing
regimen which is effective at reducing parasite biomass by four orders of
magnitude over a 48 hour period [36]. Artemether is used for the treatment of
severe malaria and in combination with lumefantrine for the treatment of
uncomplicated P. falciparum malaria. Artemether-lumefantrine is taken as a sixdose regimen and has been highly effective against multidrug resistant P.
11

falciparum [107-109]. Following the 1999 registration of the drug in Switzerland,
resulting from a collaboration of Novartis and the Chinese developers, it was
dually branded and marketed as Riamet® in developed non-endemic countries
and as Coartem® in malaria endemic countries [106]. Artesunate is the treatment
of choice for severe malaria and has been used in combination with
amodiaquine, mefloquine and pyronaridine [36, 106]. Artesunate-mefloquine has
been widely used in South East Asia and is effective against multidrug resistant
P. falciparum. Artesunate-amodiaquine has variable effectiveness and is
acceptable for use in areas where amodiaquine resistance is low. Artesunatepyronidine has been used for the treatment of malaria since the 1980s and has
been effective against malaria in Africa, but less effective in Thailand [106].
Artemisone is a promising second-generation derivative with a longer half-life,
lower curative dose, greater bioavailabily compared to the other derivatives, and
did not display neurotoxicity in preclinical testing [105, 110]. Another
endoperoxide drug, the synthetic peroxide OZ439, was designed to provide a
single dose oral cure in humans. It is fast acting against all asexual erythrocytic
stages of P. falciparum [104]. The peroxide, OZ277 was the first synthetic
ozonide to be evaluated clinically as a combination therapy with piperaquine
phosphate. It exhibits activity against all asexual development stages and is
currently in Phase III trials [104, 111].
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Quinolines
The quinolines target heme polymerization in the erythrocytic stages of
Plasmodium development. Blocking this process promotes the accumulation of
toxic free heme that eventually leads to the death of the parasite [38, 95, 112114]. Two subgroups of these compounds, the 4-aminoquinolines and the 8aminoquinolines differ in the position of the amine group.
4-Aminoquinolines
Compounds within this group have been effective against erythrocytic and
sexual stages of Plasmodium in vivo and in vitro. These compounds have a
history of being safe and economical, but emerging drug resistance has
increased the need for alternative analogues [95, 98]. Chloroquine (CQ) is one
of the most widely used drugs for treating malaria. It was mainly affective against
erythrocytic stages of each of the human strains of Plasmodium and
gametocytes of P. vivax [95]. Emerging resistance in P. vivax to CQ is beginning
to limit its effectiveness, but it is still effective in most P. vivax endemic areas.
Hydroxychloroquine is a variation of CQ with a hydroxyl group added to the sidechain. The activity and mechanism is similar to CQ and it is prescribed to treat
the same types of infections [64]. Amodiaquine has been in use for more than 40
years, and is similar to CQ in both structure and activity [101]. This drug has
been useful due to its effectiveness against some CQ resistant strains [115].
Another drug, naphthoquine, is effective against schizonts when used as a
monotherapy [116]. Though naphthoquine has proven effective against some
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CQ resistant strains, other recent applications combine it with artemisinin [96,
107, 116, 117]. Piperaquine is an orally active option that is more effective than
CQ against P. falciparum [106]. It was first synthesized in the 1960s in China
and has been just as effective as CQ against P. falciparum and P. vivax. This
drug has also been combined with DHA, and following approval by the European
Commission in 2011, it was marketed as Euratesim®. This ACT is administered
once a day for 3 days, and provides longer protection against new infections than
other ACTs [93, 109, 118, 119]. Pyronidine, in combination with artesunate is
administered in a similar 3-day fixed-dose regimen. As a monotherapy,
pyronidine is effective against drug-resistant P. falciparum malaria, and is also
used on combination with arteminins [120]. Tert-butyl isoquine was developed
as a drug candidate as part of a public-private partnership and demonstrates
excellent activity against P. falciparum both in vitro and in vivo. It is still under
investigation as a potential future antimalarial [121]. Amodiaquine-13 is another
analogue of CQ that is active against CQ-resistant strains [122].
8-Aminoquinolines
One of the most commonly used drugs within this group is primaquine,
which is effective against gametocytes with low activity against erythrocytic
stages, and is the only drug that can clear dormant (hypnozoite) liver stage
infections of P. vivax [113, 123]. Monotherapy using primaquine has been
permitted in some endemic regions and it is also recommended as a follow-up
treatment to ACTs [38]. A variation of primaquine, diethylprimaquine is effective
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preventing exflagellation, however, its activity is similar to another derivative
bulaquine with lower efficacy than primaquine against drug resistant strains [64].
Tafenoquine is also effective against hypnozoites and can be taken as a 2-3 day
treatment course [124]. However, use of these drugs has been known to be
associated with increased risks of hemolysis in glucose-6-phosphate
dehydrogenase (G6PD) deficient patients [81]. This is due to the formation of a
reactive quinone imine and peroxy radical that would be toxic in the absence of
G6PD [38]. Due to its major toxicity in humans, development of NPC-1161B
provided a new lead compound, which has reduced hematological toxicity and
promising efficacy against P. vivax [124, 125].
Antifolates
Development of antimalarials from this group was based on the
understanding of folate derivatives in humans [126]. In the early 1930s folic acid
was identified as a factor able to reverse some forms of anemia. Later,
development of antifolate agents was carried out to treat leukemia. All the
antifolates have a greater affinity to P. falciparum dihydrofolate reductase
(PfDHFR), accounting for the favorable therapeutic index [126]. One study
suggested that the difference in affinity is due to the different methods of
regulation where the parasite form is less readily replenished when targeted by
inhibitors [3]. However, the hypothesis requires further investigation since it
could not be confirmed in a subsequent study [127]. For the treatment of
malaria, this group is subdivided into two categories, class I (dihydropteroate
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synthase inhibitors) and class II (dihydrofolate reductase inhibitors) antifolates,
and when used in combination, both classes work synergistically in treating
malaria infections [126]. Proguanil was the first antifolate developed in 1945, and
was found to be more effective than quinine in animal models [126, 128]. It also
has a derivative cycloguanil, which has been effective in treating cases of drug
resistant infections [129]. Proguanil has been used both as a monotherapy, and
more recently, in combination with atovaquone (Malarone®), as a prophylactic, to
inhibit electron transport to the cytochrome bc1 complex [126, 130]. There is
also a chlorinated variant of proguanil, chlorproguanil, that is used less
frequently. Due to higher potency, chlorproguanil is recommended as a
prophylactic at a lower dose. It was developed through a collaboration of
GlaxoSmithKline (GSK), Liverpool University and WHO/TDR in East Africa, and
is more effective than sulfadoxine-pyrimethamine [106]. When used in
combination with Dapsone (LapDap), chlorproguanil was found to be more potent
and retain activity against sulfadoxin-pyrimethamine resistant strains [97, 126,
131-133]. Pyrimethamine (Daraprim®) was identified when antifolate analogues
were being tested in the treatment of tumors. Because of a structure similar to
that of proguanil, pyrimethamine was hypothesized to have antimalarial activity
and was later screened against the parasites [134, 135]. In practice it is mostly
used in combination with sulfadoxine with limited use as a monotherapy [126].
Eventual emerging resistance to antifolates prompted the development of
additional effective compounds, and this led to development of P218 that was
deemed suitable for initial studies in humans [136].
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Sulfonamides
Sulfonamides, also known as sulfa drugs, completely inhibit folic acid
synthesis in microorganisms. As class I antifolate inhibitors, these compounds
block dihydropteroate synthase. Low efficacy and toxicity discouraged their use
as monotherapy, but interest in this group was maintained due to synergistic
effects when combined with anti-DHFR compounds. Dapsone, in addition to
being combined with chlorproguanil, has also been combined with pyrimethamine
(Maloprim®). Pyrimethamine is also combined with sulfadoxine (Fansidar®),
sulphalene (Metakelfin®) as well as sulfamethoxazole and sulfadiazine [137139].
Amino Alcohols
Amino alcohols are widely used in combination with artemisinin derivatives
and have been affective against resistant parasite strains. One of the prominent
amino alcohols lumefantrine is typically administered in combination with
artemether (Coartem®) [36, 140].
Kinases and Phosphatases of Plasmodium
Bioinformatic characterization of PF13_0027 in PlasmoDB identifies it as a
putative phosphatase due to presence of a conserved DUSP. Tandem
arrangement of the DUSP and the RHD suggest that it is homologous with a
class of phosphatases known as MKPs that are typically characterized with a
similar domain arrangement. The unique phenotype resulting from the disruption
of PF13_0027’s open reading frame led us to investigate the P. falciparum
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pathways involving proteins with similar characteristics. Interestingly, the MAPK
signal transduction pathway is a well characterized pathway in several
eukaryotes responsible for multiple intracellular processes when disrupted might
result in an attenuated phenotype similar to the one observed in the C9 mutant
parasite. Functions affected by MAPK pathways are typically utilized to regulate
critical cellular process such as stress response, osmoregulation, cell cycle
regulation, signal transduction, or transcription factor interaction (Figure 1.4)
[141-145]. It is our current understanding that in P. falciparum these pathways
could be utilized in a similar fashion [146-154]. It is likely that the phenotype of
C9 parasites results from disrupting one or more of these pathways, however
further investigation would be necessary to confirm this assertion. Furthermore,
since protein phosphatases are integral to cell survival, this putative phosphatase
provided a novel subject for investigation. Therefore, my hypothesis is that
PF13_0027 functions as an important component of intraerythrocytic
development.
Protein kinases occupy an important role in eukaryotic cell development
by regulating the activity of various proteins through additive phosphorylation.
Phosphatases serve an antagonistic function, removing phosphate groups,
throughout cellular development and response to external stimuli, which when
knocked out, can result in aberrant or deleterious effects on development.
Phosphorylation cascades have become the focus of many studies in
Plasmodium because of their deduced importance for development. Much of the
literature investigates their involvement in cascades regulating the progression
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from gametocyte to the formation of the zygote and oöcyst in the mosquito
midgut [142, 154-158]. Given the level of importance that phosphorylation and
dephosphorylation serve in cellular development, further investigation of this
process is vital to expanding our knowledge of this malaria parasite’s biology. In
studying these pathways it is also important to consider the relationships of both
kinases and phosphatases.
Plasmodium Kinases
Exhaustive evaluation of the kinome in model organisms such as C.
elegans, D. melanogaster, S. cerevisiae and H. sapiens resulted in the
identification of 7 groups of protein kinases. These groups are the cyclicnucleotide and calcium/phospholipid-dependent kinases (ACG group); the
CMGC group, comprised of cyclin-dependent kinases (CDK), mitogen-activated
kinases (MAPK), glycogen-synthase kinases (GSK) and CDK-like kinases;
calmodulin-dependent kinases (CamK) group; tyrosine kinases (TyrK) group
which is absent from Plasmodium; casein kinase 1 (CK1) group; the sterile (STE)
group, also absent from Plasmodium; and the tyrosine kinase-like (TKL) group
[159-161]. Another important group to acknowledge in Plasmodium is the
orphan protein kinases (OPKs) that do not share any homology with mammalian
kinases and possess atypical enzymes with features from more than one family
of kinase [162].
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The ACG Group
There are five Plasmodium phosphatases from this group; cAMPdependent kinase (PfPKA, PFI1685w), cGMP-dependent kinase (PfPKG,
PF14_0346), PKB-like serine/ threonine kinase (PfPKB, PFL2250c) that
functions in the phosphoinositide-3-kinase (PI3K)-dependent pathway. Aurora
related kinase (ARK2, PFC0385c) a putative serine/ threonine kinase involved in
kinetochore organization, and PF11_0464 a putative serine/ threonine kinase
[159, 163-165].
The CMGC Group
Kinases within the CMGC group [cyclin-dependent kinases (CDK),
mitogen-activated kinases (MAPK), glycogen-synthase kinases (GSK) and CDKlike kinases] control cell proliferation and development and in the Plasmodium
kinome, they make up the most prominent kinase group. This group includes the
CDKs which regulate cell-cycle progression, several of which have been
identified in Plasmodium [162, 166]. These kinases include; PfPK5
(PF14_0605), PfPK6 (MAL13P1.185), Pfmrk (PF14_0605), Pfcrk-3 (PFD0740w),
Pfcrk-4 (PFC0755c) and Pfcrk-5 (PFF0750w) [159, 166]. Pfcrk-4 and PfPK6
both have features of CDKs and MAPKs and form a cluster at an intermediate
position between both groups in phylogenetic analysis [159].
The two MAPKs, Pfmap-1 (PF14_0294) and Pfmap-2 (PF11_0147) serve
a critical function as transducers of intra- and extracellular signals to cell cycle
control elements and transcription factors [162]. Studies involving the MAPKs
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have been carried out in both P. falciparum and P. berghei resulting in numerous
insights into the biology of malaria parasites even though the roles of these two
MAPKs appear to be reversed in these Plasmodium species. During
microgamete formation in P. berghei, MAPKs are involved in control of
cytokinesis and flagellar motility [152]. Expression profiles in P. berghei have
shown that Pfmap-2 is not essential to asexual growth and gametocytogenesis,
but it is essential to microgametogenesis [142]. Contrasting results were
discovered when investigating MAPK function in P. falciparum when it was
discovered that Pfmap-2 is critical for asexual development [167]. Furthermore,
they identified that levels of Pfmap-2 were elevated in Pfmap-1-KO parasites
suggesting that not only Pfmap-2, but also Pfmap-1 have relevance to asexual
development. The CMGC group also has two GSK3-related kinases, PfPK1
(PF08_0044) and PfGSK3 (PFC0525c), as well as a LAMMER-related kinase
Clk1 (PF14_0431) [168-170]. The GSKs have a critical function in regulation of
cell proliferation and the Clks are important for RNA metabolism [162].
The CamK Group
This group occupies an important role in the development of the oökinete
in the mosquito vector. Calcium dependent protein kinases (CDPKs) make up a
family of serine/ threonine kinases found only in protozoa and plants and are
distinct from all other animal protein kinases [148, 154]. The P. falciparum
genome encodes 6-7 CDPKs that are developmentally restricted to Ca2+
signaling. This group is characterized by the presence of a kinase catalytic
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domain located adjacent to four EF-hand calcium binding domains, an overall
structure that is shared with CDPKs of plants and ciliates [159]. PfCDPKs 1-3
and 5 (PFB0815w, PFF0520w, PFC0420w and PF13_0211 respectively) are
expressed throughout the asexual stages while PfCDPK4 (PF07_0072) is
expressed in the sexual stages [171-174]. PfCDPK4 is essential for the
development of parasites in the mosquito during male gametocyte exflagellation
[154, 159]. CPDK4 specifically is one of the kinases responsible for the
transduction of the Ca2+ signals within the parasite prior to the differentiation of
the gametocyte to the microgamete. When CDPK4 is knocked out in P. berghei,
parasites fail to produce oöcysts supporting the understanding that its expression
is essential to reproduction [154]. PfCDPK7 (PF11_0242) is similar to the other
CDPKs with the exception that it contains one EF-hand motif. An additional
branch of the CDPK group is PfPK2 (PFL1885c) and PfCDPK6 (PF11_0239) that
do not have the EF-hand motif [175, 176].
The CK1 Group
Plasmodium only has one characterized kinase in this group, PfCK1
(PF3D7_1136500.1) [159, 177]. Though it is able to phosphorylate several
proteins in vitro, the role of has not been determined [162].
The TKL Group
In this group, of the four malarial enzymes, three kinases, PfTKL4
(PFF1145c) and PfTKL1 (PFB0520w), and PfTKL2 (PF11_0220) share
homology with MAPKKK-related enzymes [159, 161, 178]. PfTKL3 (PF13_0258)
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has a sterile α-motif (SAM) domain dependent kinase expressed in both asexual
development and gametogenesis and is being studied as a viable drug target
[178].
The OPK Group
The NIMA-related kinases (Nek) family is responsible for centrosome
replication during eukaryotic cell division [162, 179]. Pfnek-1 (PFL1370w), which
has been shown to phosphorylate Pfmap-2, is predominantly expressed in both
the asexual and sexual stages. Interestingly, the P. berghei ortholog of Pfnek-1
is only expressed in the microgametocyte which is consistent with the suggestion
that Pfnek-1 is important for male gametogenesis [162, 180, 181]. The
remaining, Pfnek 2-4 (PFE1290w, PFL0080c, and MAL7P1.100 respectively) are
expressed in gametocytes [162, 182]. Studies with the Pfnek-4 ortholog in P.
berghei have revealed that Pbnek-4 is essential for oökinete maturation,
revealing another possible role of the Neks [183].
Plasmodium Phosphatases
Phosphatases dephosphorylate proteins reversing and controlling the
actions of protein kinases. This function is critical to cell viability since
unregulated kinase activity can have detrimental effects [184]. Earlier research
had characterized two main functional groups of protein phosphatases; protein
tyrosine phosphatases (PTP) that are typically membrane associated and protein
serine/threonine phosphatases (PP) that are cytosolic [185, 186]. The members
of these phosphatase families have high sequence conservation within the active
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site and participate in regulation of cell cycle progression, protein synthesis,
carbohydrate metabolism, transcription, and neuronal signaling in eukaryotic
cells which underscores their importance to survival [185]. Furthermore, within
the PPs, there are two distinct sub-families; Mg2+-dependent phosphatases
(PPM) and Mg2+-independent phosphatases (PPP) [186]. This group is
subsequently divided into more specific groups, PP1 (PF14_0142), PP2A, PP2B
and PP2C. With respect to PP2C, studies carried out in Toxoplasma gondii
determined it to have a significant effect on the host cell following invasion [187].
One study revealed this using GFP fusion tags to localize PP2C and determine
that the nuclei of host cells were the targets, and that the protein was being
released from the bulbous region of the rhoptries of the invading parasites [188].
In recent years, advances in our understanding of phosphatases have led to the
identification of additional classifications. Within the genome of Plasmodium,
four groups of phosphatases are represented: The PPP group; the PPM group;
the PTP group; and the NLI-interacting factor like (NIF) group (Table 1.1) [2].
The PPP group
The phosphatases of this group are highly conserved and among the most
extensively studied type of protein phosphatases [189, 190]. These enzymes
target a large variety of substrates that are not limited to phosphoproteins, since
they are similar to the metallophosphatases in their dependency on Mn 2+, Ca2+,
and/ or Co2+. Classification of subgroups has been recently extended to include
as many as eight distinct subtypes of serine/threonine phosphatases (PP1,
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PP2A, PP2B, PP4, PP5, PP6, PP7 and BSU (plant-specific) [191, 192]. There
are also three conserved motifs that have been considered as the signature motif
of the PPP family (GDXHG, GDXXDRG and GNH [E/D]) [191-194].
Within Plasmodium, several PPs have been identified. PF3D7_1466100
(BSU subfamily) is a PP1-related enzyme with closely related orthologs in plants
encoding Kelch motifs in the N-terminal domain. These Kelch motifs form distinct
tertiary structures that are thought interact with regulatory subunits [195, 196].
Another such phosphatase, PF14_0142 (PP1 subgroup), is expressed in all
stages of the developmental cycle with a slight reduction during the late
trophozoite stage [2]. PF14_0224 (PP7 subgroup) has metal (Mn2+) and
phosphate and water binding motifs, except there are substantial differences
from the other phosphatase subgroups. PFC0595c, similar to the PP2/4/6 type
phosphatases, is expressed with a similar profile; however, microarray data
suggests additional activity in the sexual stages [182, 197]. PF08_0129 shares
characteristics with the PP3, PP2B and calcineurin subgroups. It is
characterized as a calcineurin-type enzyme with a calmodulin-binding domain.
PFI1245c is part of the PP2 subfamily and is homologous to the mammalian
phosphatase PP2A. These phosphatases are asparate-rich proteins with the
ability to inhibit the phosphatase PFI1245c. Subgroup PP5 phosphatases are
represented in the Plasmodium phosphatome by MAL13P1.274 that contains a
nuclear targeting sequence in the N-terminus as well as TPR (tetratricopeptide)
repeats [2]. Phylogenetic analysis of PFI1360c identifies it as closely related to
the PP2/4/6 subgroups. Previous data has suggested that it may be involved in
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centrosome maturation, spliceosome assembly, chromatin modification and
regulation of the NF-κB and mTOR signaling pathways [2, 193].
The PPM Group
This group is made up of a diverse set of enzymes with Mg2+ and Mn2+
dependent phosphatase activity that typically function in modulating stress
responses. They typically have regulatory domains in the N- or C-terminal
extensions [2]. Despite structural similarities between this group and the PPP
group, they do not share sequence homology [198, 199]. Also a PP2C-type
phosphatase PF11_0396 has been reported for Plasmodium in literature
suggesting that it regulates translation factor 1B [2, 187]. Two other PPM-related
phosphatases are PFE1010w and MAL8P1.109, but they do not have any
experimental data to support a suggested function.
The PTP group
The group is subdivided into three main subfamilies; the PTPs, the
DUSPs, and the low molecular weight phosphatases [200-204]. Eukaryotic
phosphatases of the PTP and DUSP subgroups are required for signaling, cell
growth, differentiation and control of the cell cycle [205]. Since the P. falciparum
cell cycle is also driven by sequential activation of CDKs [146], the phosphatase
CDC25 is an essential regulator of the cell cycle that works by activating the
CDKs through dephosphorylation at the G2-M transition [151, 206, 207]. In
contrast, humans have three CDC25s (CDC25A, CDC25B and CDC25C) that
dephosphoryate the threonine and tyrosine residues in order to trigger activation
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of CDK/cyclin activity. The CDC25 phosphatases form a distinct group which
has little sequence similarity with the other PTPs except for the signature motif.
They appear to have evolved from RHDs that have been known to catalyze
sulfur-transferase reactions [147]. These types of phosphatases are essential for
differentiation of the gametocyte to the microgamete since this transition is
dependent on the three rounds of division that producing eight motile
microgametes [208]. The microgametes, when fused with the macrogamete,
form the zygote that further differentiates to the oökinete, which migrates through
the midgut wall [152].
The conserved catalytic mechanism of these enzymes is mediated by
cysteine, arginine and aspartic acid residues comprising the Cx5R signature
motif [2]. Within P. falciparum some PTPs have been investigated biochemically
[209, 210]. The first PFC0380w (YVH1) contains a Zn2+-binding domain,
exhibiting activity against phosphorylated serine and threonine residues. The
second, PF11_0139 (PRL, “Protein of Regerating Liver”)) is a protein tyrosine
phosphatase with the CaaX motif in the C-terminal motif used for farnesylation. It
has also been identified as a target of farnesyl-transferase. In merozoites, it colocalizes with AMA-1 and may be involved in invasion [2, 210]. Within this group,
the phosphatase MAL13P1.168, which as similar structure to the PTP family, is
characterized as having a PTP-like motif. The catalytic site contains a
substitution of a proline in place of arginine in the catalytic site [2, 211]. Similar
to this substitution, PF13_0027 has an isoleucine substitution in place of the
conserved arginine in the catalytic site.
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The NIF group
Phosphatases in this group are responsible for the dephosphorylation of
the carboxy-terminal domain of RNA polymerase II. These phosphatases are
also known to interact with the transcription factor TFIIF. They are believed to
dephosphorylate serine in the C-terminal to reactivate the polymerase after
transcription termination [212-216]. P. falciparum has four identified genes within
this group. The NIF phosphatases have a distinct DxDx(T/V) motif in the active
site that is conserved in two of the sequences, PFE0795c, and MAL13P1.275.
The third sequence PF10_0124 is closely related, but does not have the intact
motif, and therefore is considered to be inactive based on preliminary
bioinformatics analysis. The fourth sequence PF07_0110 falls within a distinct
clade of NIF-type domains with a disrupted DxDx(T/V) motif (Table 1.2) [2].
Focus of Study
This dissertation research project investigates the involvement of
PF13_0027 during intraerythrocytic development of P. falciparum. PF13_0027
has a DUSP domain that maintains structural homology to DUSP domains and it
is conserved across Plasmodium spp. with orthologs in other species (Table 1.3).
Attenuation of blood-stage parasite growth following functional knockout
suggests that it has an important regulatory mechanism in the developmental
cycle, specifically during the late trophozoite when it is maximally expressed.
Phosphatases have been the focus of several recent drug development
studies and it is reasonable to investigate this as a novel target since new
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mechanisms of action for antimalarial drugs are a critical priority. This priority is
emphasized by decreased drug efficacy due to increasing drug resistance. It has
also been demonstrated that cascades involving protein phosphorylation are
required for with successful development of Plasmodium parasites as well as
eukaryotic cells. Expansion of our knowledge of Plasmodium biology through the
study of PF13_0027 will augment our understanding of the regulatory processes
used by these parasites.
In addition to partially characterizing the function of PF13_0027, this
phosphatase was also evaluated as a possible drug target through highthroughput in silico techniques. Utilizing the available compound libraries in the
ChEMBL-NTD, we were able to screen a preliminary model of PF13_0027
against compounds with antimalarial activity and determine if any of these
compounds interact with the predicted active site. Several compounds were
identified and obtained for further in vitro assays and assessed for their effect on
the asexual cycle. Through this study we investigate the role of PF13_0027 in P.
falciparum and suggest a function explaining its contribution to parasite
development and evaluate it as a drug target.
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Figure 1.1: The piggyBac transposon mutagenesis system [9]. (A) The
helper plasmid carries a selectable marker for human dihydrofolate reductase
(hDHFR) under the control of a 5' calmodulin promoter and 3' calmodulin
terminator. (B) The helper plasmid codes for the piggyBac transposase
which excises the selectable marker allowing it to randomly insert into the
genome. (C) Late stage parasites are separated from mixed cultures using a
magnetic column and mixed with red blood cells (RBCs) containing the
transposon and helper plasmids. Transfected parasites are then selected by
applying drug pressure and cloned to identify parasites with single insertions.
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Figure 1.2: The spatial distribution of P. falciparum malaria endemicity in
2010 [7].
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Figure 1.3: The spatial distribution of P. vivax malaria endemicity in 2010 [6].
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Figure 1.4: Life cycle of the malaria parasite [5].
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Figure 1.5: A global map of dominant malaria vector species [4].
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Figure 1.6: Summary of the MAPK pathway.
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Table 1.1: Classifications of phosphatases [1-3].
.
Subgroup

Examples

Signature
motif

Metal ions

Phosphoprotein
phosphatases (PPP,
PPM, PP2C)

Metallophosphatases

GDxHG,
GDx2GRD
GNH[E/D]

Mn , Mg , Ca , Co

Protein Tyrosine
Phosphatases (PTP,
DUSP)

Tyrosine specific and
dual specificity
phosphatases

DXnCX5R

NLI interacting factor-like
phosphatase (NIF)

TFIIF-associating Cterminal domain
phosphatase 1 and Small
CTD phosphatases

DxDx(T/V)
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2+

Function

2+

2+

2+

Modulate stress responses (ex.
PP1, PP2A, PP2B, PP4, PP5,
PP6, PP7, BSU)

-

Cell cycle regulation and signal
transduction (ex. Cdc25, MKP)

-

Interaction with transcription
factor TFIIF, dephosphorylation
of the carboxy domain of RNA
polymerase II

Table 1.2: Phosphatases identified in P. falciparum
ID

Annotation

PPP group (Phospho-Protein Phosphatases)
PF14_0630

Protein serine/threonine phosphatase

PF14_0142

Serine/threonine protein phosphatase, putative

PF14_0224

PP1-like protein serine/threonine phosphatase

PF10_0320a

Protein phosphatase 1 regulatory subunit 7

PFC0595c

Serine/threonine protein phosphatase, putative

PF10_0177

Erythrocyte membrane-associated antigen HT; SP; API

PF08_0129

Protein phosphatase, putative

PFI1245c

Protein phosphatase-beta

PFI1360c

Serine/threonine protein phosphatase, putative

MAL13P1.274

Serine/threonine protein phosphatase pfPp5

PF13_0222

RNA lariat debranching enzyme, putative

PFL0980w

RNA lariat debranching enzyme, putative

PFA0390w

DNA repair exonuclease, putative

PF14_0064

Vacuolar protein sorting 29, putative

PF14_0036

Acid phosphatase, putative

PF14_0282

Acid phosphatase, putative

PF14_0660

Hypothetical protein; Protein phosphatase (PPP group, Shelphs bacteriallike subgroup), putative SP; API

PFL0300c

Phosphoesterase, putative SP

PF14_0614

Hypothetical protein; metallo-dependent phosphatase SP

PF10_0177a

Serine/threonine protein phosphatase, putative
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Table 1.2: Continued
ID

Annotation

PPM group (Mn

2+

MAL13P1.44

Protein phosphatase 2c-like protein, putative

PFL2365w

Hypothetical protein, conserved; Protein phosphatase (PP2C/PPM group),
putative

PF14_0523

Protein phosphatase 2C, putative

PFD0505c

Protein phosphatase 2C

PFE1010w

Protein phosphatase 2c, putative

PF11_0362

Protein phosphatase, putative

PF11_0396

Protein phosphatase 2C

MAL8P1.109

Protein phosphatase 2C, putative

PFL0445w

Conserved Plasmodium protein, unknown function; protein phosphatase

PF10_0093

Protein phosphatase, putative

MAL8P1.108

Protein phosphatase, putative

PF10_0093

Hypothetical protein; Protein phosphatase (PP2C/PPM group), putative

or Mg

2+

dependent protein serine/threonine phosphatases)

PTP group (Protein Tyrosine Phosphatases)
PF14_0524

Protein phosphatase 7 homolog, putative API

PFC0380w

Dual-specificity protein phosphatase, putative

PF11_0139

Protein tyrosine phosphatase, putative

PF11_0281

Hypothetical protein: weak similarity to dual specificity protein phosphatase

MAL13P1.168

Hypothetical protein, conserved; Protein tyrosine phosphatase

PF13_0027

Protein phosphatase, putative
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Table 1.2: Continued
ID

Annotation

NIF group (NLI interacting factor-like phosphatases)
PFE0795c

Nif-like protein, putative

PF07_0110

Hypothetical protein, conserved; CTD phosphatase

PF10_0124

Hypothetical protein; CTD phosphatase

MAL13P1.275

NLI interacting factor-like phosphatase, putative; CTD phosphatase

Others
PF14_0492

Protein phosphatase 2b regulatory subunit, putative
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Table 1.3: Orthologs of PF13_0027 [8].
Accession

Taxon

Description

PBANKA_140400

Plasmodium berghei str. ANKA

conserved Plasmodium
protein, unknown
function

PCHAS_140590

Plasmodium chabaudi chabaudi

conserved Plasmodium
protein, unknown
function

PFIT_1304700

Plasmodium falciparum IT

protein phosphatase,
putative

PKH_140400

Plasmodium knowlesi strain H

conserved Plasmodium
protein, unknown
function

PVX_122110

Plasmodium vivax SaI-1

hypothetical protein,
conserved

PY00561

Plasmodium yoelii yoelii str. 17XNL

hypothetical protein
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Chapter 2: Identification of a Putative Phosphatase in Plasmodium
falciparum Regulating Progression from Pre-S Phase Blood Stage
Development (Specific Aim 1)
Rationale for Study
Regulation and developmental checkpoints in blood-stage P. falciparum
are complex and critical components of malaria transmission. Regulation of this
important developmental phase depends on the functions of kinases and
phosphatases [143, 151, 211, 217-223]. Kinases and phosphatases modulate
the active-to-inactive state of substrates through phosphorylation-todephosphorylation, respectively. Much of the current research in Plasmodium
has focused on mechanisms controlling transcription regulation and cell
proliferation, as a target for novel antimalarials, directed at the asexual bloodstage cycle [224]. Other studies have investigated phosphorylation cascades
during the gametocyte-oökinete-oöcyst transition in the mosquito midgut [154,
225]. PF13_0027 is conserved in Plasmodium species and expressed
throughout the intraerythrocitic cycle, suggesting a conserved role throughout
parasite development. In this study, we use a PF13_0027 mutant (C9), created
by disruption of the gene’s ORF during the course of a large-scale transposon
mutagenesis project of P. falciparum, to evaluate the function and significance
during intraerythrocytic development.
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Introduction
P. falciparum is the most deadly of the five known human malaria parasite
species. It causes deaths in the hundreds of thousands each year, and millions
of clinical illnesses [10]. It is the major cause of severe malaria and grows
rapidly within the blood of infected individuals through successive cycles of
asexual growth and proliferation. Active entry into erythrocytes is followed by a
pre-S growth phase consuming the host proteins until a switch to S/M
proliferation and cytokinesis in the last third of the cycle. This process
culminates in a dynamic release of erythrocyte-invading merozoites. The rate of
growth and extent of proliferation varies among isolates and is implicitly of
importance for disease progression during an infection. Other malaria parasites
of the phylum Apicomplexa, such as T. gondii or Eimeria tenella, share this
pattern of asexual development suggesting the importance of this pattern of
development throughout the phylum [226].
In eukaryotic systems, phosphorylation cascades are critical to cellular
development and depend on the coordinated activity of kinases, which are in turn
modulated by the activity of phosphatases. There is growing evidence that
kinases are critical regulators of cell growth and development in Plasmodium
species [227-229]. Plasmodium kinases, for example, have been found to be
involved with the initial invasion of host cells in addition to egress and
differentiation [226, 230]. Additional studies have identified kinases in
phosphorylation cascades of the gametocyte-oökinete-oöcyst transition in the
mosquito midgut [154, 225, 231-235]. In contrast, few studies have described
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the phosphatases involved in these processes, which would understandably
function with kinases to co-regulate cell cycle progression at key checkpoints [2,
188, 236-238]. This dearth of information about phosphatases may be due to a
smaller relative number of identifiable phosphatases in the Plasmodium genome
compared to kinases [2, 239]. However, it is not uncommon for phosphatases to
be fewer in number due to their non-specific mechanism of targeting
phosphorylated substrates [240].
The protein tyrosine phosphatase (PTP) superfamily is defined by a
conserved CX5R motif located in a phosphate-binding pocket. Dual-specificity
phosphatases (DUSPs) are a subset of this superfamily that includes the
mitogen-activated protein kinase (MAPK) phosphatases (MKPs). MKPs are
frequently involved in regulation of cell cycle progression, growth, and
proliferation [222]. One class of MKP is characterized by the presence of a noncatalytic N-terminal rhodanese (RHD)-like domain utilized for substrate
recognition upstream from a catalytic DUSP domain [143, 153, 219]. In P.
falciparum, PF13_0027 is the only gene encoding a product with these
characteristics [2]. In this study, we hypothesize that PF13_0027 is an atypical
MAPK phosphatase of P. falciparum expressed during intraerythrocytic
development.
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Materials and Methods
In vitro Parasite Culture Conditions
P. falciparum NF54 and mutant C9 clones were cultured according to
standard methods at 37°C (5% O2 and 5% CO2, nitrogen balanced) in 5%
hematocrit (O+ blood) and RPMI 1640 medium with and 0.5% Albumax II, 0.25%
sodium bicarbonate and 0.01 mg/ml gentamicin [241]. The C9 mutant parasite
line was created by random insertional mutagenesis using the piggyBac
transposon pXL-BACII-HDGH (Appendix A). The location of the insertion in the
PF13_0027 ORF was confirmed by thermal asymmetric interlaced (TAIL)
sequence analysis.
Determination of Merozoite Number Per Schizont
Parasite cultures were synchronized with 5% sorbitol [241]. Merozoite
numbers were counted in 300 segmented schizonts in Giemsa-stained thin
smears from NF54 and C9 parasites to determine average number of merozoites
produced per schizont.
RNA Extraction and Analysis by qRT-PCR and RT-PCR
NF54 RNA was collected from six intraerythrocytic developmental stages;
early rings, late rings, early trophozoites, late trophozoites, early schizonts and
late schizonts (ER, LR, ET, LT, ES and LS, respectively) followed by saponin
lysis and suspended in TRIzol® reagent (Life Technologies™), RNA purified, and
treated with DNase I. Purity was confirmed by PCR carried out without the
addition of reverse transcriptase. PF13_0027 transcripts were amplified using
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primers 5′-TCGATTTTGAGGAGCTGAA-3′ and 5′GGGTAAAACATCCTTTTTGTT-3′ with SuperScript® III Platinum® SYBR® Green
One-Step qRT-PCR Kit (Life Technologies™) following the manufacturer’s
protocol. For RT-PCR analysis, 100 ng DNAse1-treated total RNA was amplified
using primers 5′-CACCATGGAATATAAAAGCATCGATTTTG-3′ and 5′GTTTATGTAATTATTTATTACTATAAATGGTC-3′, and analyzed by horizontal
agarose gel electrophoresis.
Plasmid Constructs and Genetic Complementation
The plasmid was developed with the full-length PF13_0027 ORF and its
native 5ʹ untranslated region (UTR), a C-terminal hemagglutinin (HA) tag and the
3ʹ UTR calmodulin (CAM) termination sequence. For drug selection, the plasmid
carried a blasticidin S deaminase (BSD) drug selection cassette under control of
5′UTR of histidine rich protein (HRP3) and 3′ UTR histidine-rich protein-2
(HRP2). Mutant variations of PF13_0027 were generated using the
complementation plasmid by site-directed mutagenesis of the conserved cysteine
(C383A), aspartic acid (D345A), and the two conserved lysines (K388A and
K394A).
Schizonts were isolated from a 20 mL culture with 3-5% parasitemia using
a VarioMACS™ Separator (Miltenyi Biotec) and counted with a hemacytometer.
Fresh 50% hematocrit blood was washed and combined with Cytomix [241] in a
1:1 v/v ratio and aliquot into chilled 2 mm cuvettes, and electroporated using a
Gene Pulser Xcell CE™ (Bio-Rad) to load RBCs with transposon and helper
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plasmids purified using methods described previously [9]. Positive transfected
clones were selected using blasticidin, diluted, then transferred to 96-well culture
plates and maintained for 17 days to select individual clones. Clones were
validated by PCR following transfection and drug selection to verify presence of
the correct drug selection cassette (Appendix B).
Growth Assay and Cell Cycle Determination
Growth assays for cell cycle determination were performed by maintaining
tightly synchronized cultures of P. falciparum NF54 and C9 clones at 0.5–2%
parasitemia. Time points were collected every two hours and then fixed in 0.05%
glutaraldehyde after removal of culture medium. Parasitemia was estimated
using flow cytometry as described previously [242] by staining parasites with
ethidium bromide and analyzed using an Accuri C6 flow cytometry system (BD
Accuri™). A total of 100,000 cells were counted for each sample and the data
was analyzed using CFlow Plus software (Appendix C) (BD Accuri™). The cell
cycle was determined by comparing the relative abundance of each
developmental stage at each time point according to methods developed
previously [243]. Relative fold change was determined by calculating the fold
increase in parasitemia between time zero and the endpoint. Each sample was
then plotted as a percent relative to NF54.
Invasion Assays
Schizonts were isolated from a 20 mL culture with 3-5% parasitemia using
a VarioMACS™ Separator (Miltenyi Biotec) and counted with a hemacytometer.
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Purified late-stage schizonts were used to initiate cultures in 96-well plates in
triplicate and cultured for 30 hours to allow segmentation and invasion of fresh
RBCs. Parasites were fixed and labeled for flow cytometry as stated in the
growth assay protocol and the fold increase in parasitemia over the 30-hour
assay was calculated as a representation of the percent of parasites successfully
invading and continuing through development.
Multiple alignments and phylogenetic analysis
The sequence of PF13_0027 and orthologous Plasmodium sequences
were retrieved from PlasmoDB v9.2 (www.plasmodb.org). Outlier species were
identified through BLAST searches with the DUSP domain using NCBI BLASTP.
Sequences with greatest homology to PF13_0027 were retrieved and used to
build the multiple alignments using ClustalW [244, 245]. Phylogenetic trees were
created using the Neighbor-joining method with 1000 bootstrap in MEGA5 [246248].
Southern Blot Hybridization
Genomic DNA (4 μg) extracted from transformed parasites was digested
with 10 units of SalI and DraIII (New England Biolabs®) overnight and separated
on a 0.8% TAE agarose gel. The DNA was depurinated in 0.25 M HCl,
denatured in 0.5 M NaOH/1.5 M NaCl, neutralized in 0.02N NaOH, 1M
C2H3O2NH4 and blotted overnight to a nylon membrane. A 711 bp probe was
developed against the bsd drug selection cassette using primers 5′ATAAGAAGAAGTATATAATGAATTATATATAATGCT-3′ and 5′47

CATATGTATTTTTTTTGTAATTTCTGTGTTTAT-3′. The blot was then
hybridized to 32P-labeled probe washed three times in 2X SSC/0.5% SDS (1X
SSC/0.15 M NaCl/ 0.015 M NaC6H5O7, pH 7.0) for 15 min, and exposed to a
Kodak photographic film at -80°C to visualize the hybridized fragments (Appendix
D).
Results
Identification of an Attenuated Growth Mutant in P. falciparum
A collection of unique mutant clones was created from a laboratory line of
P. falciparum NF54 using random insertional mutagenesis with a piggyBac (pB)
transposon [9]. The C9 parasite line carried one copy of a pB transposon (pXLBACII-HGDH) inserted near the 5′ end of the single ORF of PF13_0027 (Fig.
2.1). Intraerythrocytic growth for clone C9 was analyzed and determined to be
severely attenuated with a net growth rate consistently 50% of the NF54 parent
(Fig. 2.2). During development, intraerythrocytic stages did not demonstrate any
obvious differences in morphological characteristics (Fig. 2.3), and mean
numbers of merozoites produced did not vary significantly from the NF54 parent
(Fig. 2.4).
Defining Characteristics of PF13_0027
The protein encoded by PF13_0027 was determined to have two key
structural features, a RHD domain followed by a DUSP-like domain.
Bioinformatics analysis defined this tandem arrangement as characteristic of
certain MKPs conserved within humans and other model organisms such as fruit
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fly and yeast [145, 221, 249, 250]. It is for this reason that we refer to the
PF13_0027 product as P. falciparum MKP. The conserved signature motif of
CX5R, which is typically definitive of DUSP domains in MKPs, is only partially
conserved in PF13_0027 (Fig. 2.5A). The putative binding pocket of PF13_0027
was identified through BLAST searches and multiple sequence alignments with
MKPs that have 3-D crystal structures (Plasmodb version 9.2; NCBI GenBank
Flat files release 193.0). Within this binding pocket the amino acid residue
cysteine-383 (C383) along with another residue of the catalytic triad aspartate345 (D345) are conserved and align with conserved cysteine and aspartic acid of
the other identified DUSPs. However, the third conserved catalytic residue,
arginine, aligns with isoleucine-398 (I398) in PF13_0027. During
dephosphorylation, the conserved arginine is critical for dephosphorylation
activity, since active DUSP domains often depend on arginine to maintain the
transition state with the phosphorylated substrate [251]. Absence of arginine is
expected to drastically reduce the catalytic activity of the DUSP; therefore, this is
an important departure from the consensus motif defined for catalytically active
DUSP domain orthologs and would be expected to reduce phosphatase activity
[251, 252].
Prior mutagenesis studies and analyses of catalytic domains in the
DUSPs of model organisms suggest that unique characteristics, such as the
ones identified in PF13_0027, may be characteristic of a pseudophosphatase or
a low activity phosphatase [253-255]. Additionally, there is an insertion of nine
residues disrupting the spacing within the CX5R signature motif. Though it
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cannot be determined if this insertion changes the three-dimensional structure
within the putative binding pocket, this unique stretch of residues is conserved in
each of the Plasmodium orthologs. Conservation of these unique characteristics
in Plasmodium species supports the formation of an individual clade (Fig. 2.5B).
PF13_0027 Regulates Transition from Pre-S phase to S/M Phase
In wild-type parasites, the highest relative abundance of PF13_0027
transcripts is at the end of the pre-S development phase (i.e., late trophozoite)
during intraerythrocytic development [256]. This expression profile coincides with
the stage when the C9 mutant cycle deviates from the wild-type cell cycle (Fig.
2.6). Utilizing the detailed time course experimental protocol developed
previously [243], the timing for NF54 was determined to be 46 hours compared to
52 hours in C9 null MKP mutant. The difference resulted from a prolonged pre-S
trophozoite stage causing late entry into the S/M schizont phase. The length of
schizont development (S/M - C) was similar in C9 and NF54 making pre-S phase
the only abnormal growth phase of the intraerythrocytic cycle (Fig. 2.7).
Phenotype Rescue of Wild-type Growth by Genetic Complementation
Attenuated growth of the C9 MKP null mutant remained stable over
multiple subsequent generations suggesting that survival was not due to
phenotype reversion. This is consistent with general experience using the
piggyBac system as it is now extensively used in a number of organisms and the
transposable elements remain integrated in the genome in the absence of
transposase [9, 257-262]. However, the extended maintenance of P. falciparum
50

intraerythrocytic cultures required for transfection and the selection process in
the experimental studies increases the possibility for secondary mutations to alter
the cell cycle or cause growth attenuation. Therefore, to validate that the
phenotype was due to disruption of PF13_0027, we genetically complemented
the C9 mutant with a full-length copy of PF13_0027, including its putative
promoter region (Fig. 2.8). The 5′ intergenic region between PF13_0027 and the
upstream gene MAL13P1.28 was added to the ORF to ensure the native
promoter was included. Using the BSD resistance marker on the complement
vector, we were able to select for two independent cloned lines, E3 and E8. RTPCR analysis of both E3 and E8 revealed that the complemented parasite lines
transcribed PF13_0027 in contrast to C9 that did not have detectable transcripts
(Fig. 2.9). Through the use of whole genome sequencing (Appendix D),
Southern blot hybridization analysis (Appendix E), and PCR validation (Appendix
F), it was also determined that the complemented parasite lines maintained the
full-length copy of PF13_0027 as stable episomes. Complementation of the C9
mutant with the full-length copy of PF13_0027 rescued the phenotype of both E3
and E8 as evident by their return to normal growth (Fig 2.10). Additionally, the
invasion phenotype was also restored in complemented parasites as well (Fig.
2.11). Results from site-directed mutagenesis confirmed that rescue of the
phenotype was not achieved in the absence of cysteine or aspartic acid for
growth (Fig 2.12) or invasion (Fig. 2.13). Replacement of the conserved lysines
did not attenuate the phenotype and parasites were complemented as seen with
the unaltered ORF (Statistical tables in Appendix G). Considering the roles
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cysteine and aspartic acid play in the binding and removal of phosphates, it is a
possibility that these residues are critical to the function of PF13_0027.
Discussion
Cell cycle progression, in P. falciparum, and completion of
intraerythrocytic development is highly dependent on a precise pattern of
metabolic events. Disruption of any of the numerous biochemical pathways and
processes is anticipated to have detrimental effects on the efficiency of this
process. In our study, we discovered that normal cell cycle development was
delayed by disruption of PF13_0027, indicating that this atypical phosphatase is
a regulator of the P. falciparum cell cycle. The delayed transition from the pre-S
trophozoite to the S/M schizont suggests this transition phase during the
parasite’s intraerythrocytic growth is a cell cycle checkpoint. Rescuing the
phenotype in the null mutant through genetic complementation validated the
attenuated phenotype.
Considering the attenuated phenotype along with the homology found
between PF13_0027 and the other well characterized MKPs, it can be suggested
that this putative atypical phosphatase fulfills a similar function in Plasmodium.
MKPs of similar structure are often involved in signaling pathways, which could
be a likely function of PF13_0027 [2, 263]. Investigations in yeast demonstrate
MKPs are critical components of various signal transduction pathways that
regulate transcription and maturation, which can also have an influence on the
cell cycle [145, 250]. Disruption of such functions in P. falciparum could produce
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the phenotype observed in C9. This domain structure is not evident in any other
gene in the P. falciparum genome, but single copy orthologs are evident in all of
the other Plasmodium species with completed genomes, suggesting its function
is conserved among all malaria parasites. The presence of an RHD domain
upstream of the DUSP is consistent of a secondary regulatory function that aids
in substrate recognition and activity of MKPs [211, 219, 222]. Conservation of
this domain in PF13_0027 as determined by bioinformatics analysis implicates
MAPK-like function for this atypical phosphatase.
Identification of PF13_0027 as a putative protein phosphatase is likely due
to the partial conservation of the conserved CX5R signature motif. Each catalytic
residue is critical to optimal function of a phosphatase, and the modifications
suggest that this DUSP may not be highly catalytic or possibly a
pseudophosphatase. Non-catalytic pseudophosphatases typically maintain
structural homology with active phosphatases allowing them to trap
phosphoproteins, thereby regulating cellular functions without dephosphorylation
activity [253, 255]. One such DUSP-homology domain in pseudophosphatases
is referred to as a serine threonine tyrosine interacting (STYX) domain, which
has an endogenous substitution of one, or more, of the catalytic residues [255,
264, 265]. Reports of pseudophosphatase activity in Caenorhabditis elegans
demonstrate this function as an important role fulfilled by Egg-4 and Egg-5 in
controlling oocyte-to-zygote transition [266]. It has also been proposed that
physical access of native phosphatases is blocked by these
pseudophosphatases, which exert a “dominant negative” function, thereby
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protecting substrates from dephosphorylation [253]. This is not a surprising
regulatory mechanism considering that the DUSP binding pockets generally lack
substrate specificity. Interestingly, the Apicomplexa possess a unique group of
pseudophosphatase with long N-terminal domains and EF-hand motifs termed
“EFPPs” [267]. However a grouping of the variety of STYX domain
pseudophosphatases, which have a substitution of the cysteine residue in the
CX5R motif, has never been characterized in Plasmodium. PF13_0027 does not
have the EF-hand motif or Ca2+ binding sites typically associated with the EFPP
grouping; however, it is missing the conserved arginine that would make it a
unique classification of putative protozoan pseudophosphatase.
The pressing need for new antimalarial drugs and identification of new
targets is critical due to emerging resistance to frontline drugs and the lack of
diverse chemotherapeutic targets [36, 268]. Furthermore, there have not been
any new classes of antimalarial drugs introduced into clinical practice since 1996
[94, 269, 270]. As a result, the preferred methods for use of antimalarial drugs
have been combination therapies due to the foreseeable challenges associated
with monotherapy or highly mutable drug targets [36, 271]. Kinases and other
regulators of phosphorylation pathways of malaria parasites represent potential
high value targets for future antimalarial drugs. However, the complex processes
of phosphorylation cascades in Plasmodium are poorly understood and limit our
ability to identify the highest value targets. Our discovery of PF13_0027 as an
important regulator of the cell cycle helps elucidate the trophozoite to schizont
transition stage as a potentially vulnerable step of the developmental cycle and
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will help create new avenues into understanding Plasmodium biology. The
phenotype associated with C9 highlights this pathway and the regulated
processes as potential targets. With further delineation of the function of the
PF13_0027 and identification of its interacting partners, additional knowledge
arising from its study will aid future drug discovery.
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Figure 2.1: Growth phenotype of C9 mutant parasite is due to disruption of
PF13_0027. A schematic of PF13_0027 disrupted by a single insertion of
the piggyBac transposon.
Tandem RHD and DUSP domains are
characteristic of MKPs.
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Figure 2.2: Growth of mutant C9 parasites as a percent of NF54.
Calculation of fold change reveals that the knockout of PF13_0027
resulted in a reduced fold change of 50% relative to NF54.
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Figure 2.3: Morphologic analysis of the C9 mutant compared to NF54.
Comparison of Giemsa-stained thin blood smears of the wild-type parent NF54
and C9 did not reveal an obvious difference in major developmental stages.
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Figure 2.4: Comparison of merozoites produced per schizont in mutant and wildtype parasites. Average merozoite counts in segmented schizonts of NF54 and
C9 were not statistically different.
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Figure 2.5: Multiple alignment and phylogenetic analysis of PF13_0027. (A)
Alignment of PF13_0027 with its Plasmodium orthologs and outlier species
showing the conservation of catalytic residues (boxes). Cysteine and
aspartic acid align with all homologs. Isoleucine aligns with the position of
the conserved arginine and is conserved in all species of Plasmodium. A
string of residues (bracket) are inserted into the signature motif and is
conserved among the Plasmodium orthologs. (B) Phylogenetic analysis
using Neighbor-joining method with 1000 bootstrap shows grouping of the
Plasmodium sequences independent of the other species suggesting an
early divergence in evolutionary lineage.
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Figure 2.6: Transcription profile of PF13_0027. Analysis by qRT-PCR
showed that expression of PF13_0027 has its highest expression
relative to actin during late trophozoite 32 hours post invasion. This
stage corresponds to late pre-S development where the cell cycle of
null mutants deviates from the wild-type development pattern.
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Figure 2.7: The cell cycle of C9 null MKP mutant is altered. Cell cycle
analysis reveals a prolonged pre-S phase in mutant parasite lines. Late entry
into the S/M phase leads to an overall longer cycle time producing a slow
growing phenotype. The blue, red and green graph lines represent the relative
abundance of rings, trophozoites and schizonts, respectively. The pre-S
phase in NF54 is 26 hours followed by a 16 hour S/M and 2 hour cytokinesis
(C). In C9 the cycle time is increased by 6 hours due to the longer 32-hour
pre-S phase. Late entry into the S/M phase coincides with the timing for peak
expression of PF13_0027 suggesting that the deficiency in the mutant cycle
can be correlated to the gene expression pattern.
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Figure 2.8: Transfection plasmid used for complementation of C9. The
plasmid construct used to complement the attenuated C9 parasite line was
developed using the full-length PF13_0027 ORF inserted adjacent to a BSD
drug selection cassette.
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Figure 2.9: RT-PCR analysis of complemented parasites. Results detected
PF13_0027 transcripts in NF54 and the complemented parasites (E3, E8),
but not in C9 null MKP mutant (red arrow). As a positive control, 18S RNA
was also included for each sample (blue arrow).
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Figure 2.10: Genetic complementation of C9 mutant rescues wild-type
growth. The growth of the complemented parasites (E3, E8) were graphed
as a percent of NF54. Each of the complemented parasite lines were
statistically the same as wild type NF54 demonstrating successful rescue of
the phenotype.
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Figure 2.11: Genetic complementation of C9 mutant rescues wild-type
invasion. The invasion phenotype of the complemented parasites (E3, E8)
were graphed as a percent of NF54. Each of the complemented parasite
lines were statistically the same as wild type NF54 demonstrating
successful rescue of the phenotype.
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Figure 2.12: Growth phenotype is not rescued when conserved residues
are mutated. Mutant constructs of the complementation plasmid were
developed. Two single mutants (C383A and D345A respectively) and
one double mutant (K388A, K394A) were used to complement C9. The
phenotype was not rescued with the C383A and D345A constructs,
however restoration of the wild type phenotype was observed in the
K388A/ K394A construct suggesting these residues are not as critical to
the function of PF13_0027.
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Figure 2.13: Invasion phenotype is not rescued when conserved
residues are mutated. The invasion phenotype of the complemented
parasites with mutations was compared to NF54. The results were
consistent with the growth assays showing phenotypic rescue in only the
double lysine mutant.
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Chapter 3: Identification of Novel Inhibitory Compounds and Evaluations
of Plasmodium falciparum Susceptibility (Specific Aim 2)
Rationale for Study
As the causative agent of malaria, P. falciparum poses a great threat to
global health, and the need for effective drugs is a high priority. Currently,
emerging resistance to several of the most common antimalarials has intensified
the need for drugs with novel mechanisms [20, 36, 38, 40]. A potential new
target is PF13_0027 that was identified through the course of a large-scale
random insertional mutagenesis project. In this current study we were able to
build on this discovery to identify molecular inhibitors from the European
Molecular Biology Laboratories database of bioactive drug-like small molecules
for Neglected Tropical Disease (ChEMBL-NTD) through high-throughput in silico
screening (HTS) with a homology model of the DUSP domain. The homology
model of the tertiary structure of PF13_0027 was generated using the resolved
crystal structure of the human phosphatase MKP3 as a template. The binding
pocket was identified readily by a sequence similarity search and multiple
sequence alignments. Then the pocket was cross-referenced with results from
the computed atlas of surface topography of proteins (CASTp) server for
validation. In silico high-throughput docking screens identified seven antimalarial
compounds from ChEMBL-NTD which were selected for functional analysis. The
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compounds were evaluated against P. falciparum NF54 for their ability to alter
the parasite’s cell cycle in a fashion similar to the attenuated C9 mutant. At least
one of the compounds extended the normal cell cycle length producing a
phenotype similar to the C9 attenuated mutant. Through this study we
demonstrate the potential for the phenotype of a pB mutant to guide identification
of novel target-specific antimalarials.
Introduction
Malaria primarily affects tropical and subtropical regions worldwide, putting
approximately 40% of the global population at risk [272]. In these endemic
regions, pregnant women and children are at the greatest risk and emergence of
antimalarial drug resistance has intensified efforts in search of new
chemotherapeutic agents [38, 59]. Currently the most effective drug for dealing
with malaria infections is artemisinin. In an effort to decrease further
development of multi-drug resistance, ACTs are the recommended first line
therapy endorsed by the WHO [36, 40, 273]. This strategy has been highly
successful in treating cases of uncomplicated malaria for several years, however
recent emergence of artemisinin resistance has become a concern [36]. Use of
artemisinin derivatives as monotherapies or sub-therapeutic dosages has
contributed to the increase of insensitive Plasmodium strains [36]. With this
spread of antimalarial resistance, identification of new antimalarials is a priority.
Widespread use of computational HTS has allowed large sets of compounds to
be investigated for biological activity [269]. Using this method, suitable lead
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candidates can be identified from large data sets improving productivity and
lowering cost to a level more favorable than in vitro screening methods,
enhancing structure-based drug design [274, 275].
Previously we identified that PF13_0027 is homologous with the PTP
superfamily, and investigated the structural characteristics further to determine
that it is most closely related to MKPs. Closer investigation of the signature motif
revealed a native substitution (R398I), which is conserved throughout
Plasmodium spp. This single substitution in the conserved MKP homology
domain is non-consensus defining PF13_0027 is an atypical MAPK
phosphatase. We hypothesize that PF13_0027 helps regulate the MAPK
pathway and may therefore be a candidate for drug design.
The MKPs in other eukaryotes are critical for intracellular signaling in
response to numerous types of stimuli [193, 224, 276]. In Plasmodium,
processes utilizing these proteins may be vital as an intracellular response to
various external stimuli to regulate stage specific gene expression. Due to the
ubiquitous nature of this pathway in eukaryotes, MAPK signaling has been
studied extensively in model organisms such as yeast [145]. In a broader
context, increased understanding of this pathway has also contributed
significantly to cancer research [263, 277, 278].
In malaria research, MAPK pathways were determined to be critical
components of sexual proliferation and for the sexual stages [143, 151, 211, 217223]. As a potential component of the MAPK signaling pathway, the PF13_0027
MKP provides an avenue for future drug discovery and warrants further research.
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Conservation of PF13_0027 orthologs in Plasmodium suggests functional
significance in parasite blood-stage development as well. Using the DUSP
domain of PF13_0027, a homology model was generated and used to screen
ChEMBL-NTD. This study utilized the distinct structural features of PF13_0027
to select an effective drug against this P. falciparum target.
Materials and Methods
Identification of Conserved Domains and Evolutionary Lineage
The sequence of PF13_0027 was retrieved from a public database [279].
The physicochemical parameters of the amino acid sequence were determined
using ProtParam [280]. The conserved domains were identified using the
Conserved Domains Database (CDD) [281], Conserved Domain Architecture
Retrieval Tool (CDART) [282], InterProScan [283, 284], Prosite [285, 286],
Superfamily [287], and the Simple Modular Architecture Research Tool (SMART)
[288, 289]. Ortholog searches were done using NCBI protein BLAST (BLASTP)
with the full deduced amino acid sequence and individual domains. Multiple
sequence alignments were constructed from the retrieved sequences with the
lowest E-values to identify conserved regions. The phylogenetic tree was
inferred using the Neighbor-joining method computing the evolutionary distance
using the Poisson correlation method with the Molecular Evolutionary Genetics
Analysis software (MEGA5) [247, 290, 291].
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Evaluation of Secondary Structure and Post-translational Modifications
The secondary structure of PF13_0027 was evaluated using JPRED [292]
and PSIPRED [293, 294]. Phosphorylation sites were assessed using NetPhos
2.0 [295] which identifies serine, threonine and tyrosine phosphorylation sites,
and NetPhosK 1.0 [296] to identify kinase binding sites. Prediction of a signal
peptide and cleavage site was searched using Signal IP 3.0 [297]. Mitochondrial
and plastid targeting sequences were searched using the prediction servers
Predotar [272] and PATS [298-300]. N-terminal myristoylation was investigated
using the Myristoylator from ExPASy [301].
Molecular Modeling and Structure Validation
The three-dimensional structure of PF13_0027 has not been resolved so a
homology model was built using the automated protein structure homology
modeling server Swiss-Model. Suitable templates for modeling were identified
using PSI-BLAST in the Swiss-Model repository [205, 302-304]. The crystal
structure of MKP3 (NCBI Accession No. 1MKP_A) was the most suitable of the
available templates with greatest sequence coverage and similarity [305]. The
remaining residues of PF13_0027 not showing any significant similarity were not
included for homology modeling. The model was assessed using the atomic
empirical mean force potential with Atomic Non-Local Environment Assessment
(ANOLEA), empirical force field with Gröningen Molecular Simulation program
(GROMOS), and QMEAN6 [303, 306]. The stereochemistry was assessed with
a minimum resolution of 2.5 Å using PROCHECK [307]. The final structure was
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also compared to the predicted secondary structure represented using DSSP
and PROMOTIF [308]. ERRAT plots were generated to check structure quality
of the template and homology structure using a nine residue sliding window
[309]. This process was repeated in an iterative fashion until all the residues in
the plot were not below 95% as done previously [310]. The quality of the final
structure was also verified using Verify 3D, Procheck and Ramachandran plots
[307, 311, 312].
Identification of the Binding Pocket
The binding pocket was identified using Pocket Finder and Q-site finder
which uses the Ligsite algorithm [76, 313, 314]. The output of the predicted
binding pocket was also compared to the Computed Atlas of Surface Topography
of proteins (CASTp), which uses the alpha shape theory pocket algorithm [315317]. The identified pocket was also validated through comparison to the
structural alignment of the resolved homology model and template (MKP3).
Selection of the Compound Dataset and High-throughput in silico Docking
All docking and scoring calculations were performed using the 2012
Schrödinger Suite. The compound library was retrieved from ChEMBL-NTD
(ftp://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLNTD/) and prepared using
LigPrep (LigPrep v2.5, Schrödinger LLC). The homology model, made from
sequence PF13_0027, was minimized using the OPLS2005 [318] force-field
algorithm and the grid files were generated in GLIDE (Glide v5.8, Schrödinger
LLC) [319-321]. The modeled structure was used to identify small molecular
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inhibitors with affinity to the predicted active site through in silico docking
experiments using extra precision (XP) mode [321] on a Dell Precision 490
workstation with an Intel Xeon dual quad-core processors running Ubuntu
10.04. From the results obtained, the molecule structures with the highest
predicted affinity; lowest docking scores within GLIDE's error of 2 kcal/mol to the
active site were selected. From this subset, the commercially available
compounds were identified and used for in vitro culture assays.
In vitro parasite culture conditions
P. falciparum NF54 and C9 were cultured according to standard methods
at 37°C (5% O2 and 5% CO2, nitrogen balanced) in 5% hematocrit (O+ blood)
and RPMI 1640 medium with 0.5% Albumax II, 0.25% sodium bicarbonate and
0.01 mg/ml gentamicin [241].
In vitro Drug Susceptibility Assay Using SYBR Green I
Synchronized cultures were seeded into 96-well plates at 0.5%
parasitemia and cultured for 96 hours under the previously stated conditions.
Plates were then frozen overnight at -80C. Plates were thawed for 15 minutes
then mixed by pipetting. Eighty microliters of each well were transferred to a new
96-well plate followed by 100 µL of SYBR Green I (Sigma Aldrich) in lysis buffer
(0.2 µL of SYBR Green I/mL 2X lysis buffer). Plates were covered and incubated
in the dark for 1 hour at room temperature. Fluorescence intensity was
measured with a SpectraMax M2e microplate fluorescence reader (Molecular
Devices) with excitation and emission wavelengths of 485 nm and 525 nm
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respectively. The sample values were expressed in relative fluorescence units
(RFU). EC50 values were obtained by normalizing the values using control wells
of samples cultured without drug and plotted using a one-phase exponential dose
response curve using GraphPad Prism 6 (GraphPad Software Inc.).
Growth Assay and Cell Cycle Determination
Parasite cultures were maintained in 96-well plates for 96 hours. Parasite
cultures were plated in triplicate with sample collection at six hour intervals.
Relative fold change of parasite growth in treated cultures was estimated by
using ethidium bromide intensity as an index for parasite growth and quantified
using flow cytometry (Appendix C). Parasite cultures were fixed in 0.05%
glutaraldehyde after removal of culture medium and permeabilized with 0.3%
Triton-X 100. Cultures were then treated with 0.5 mg/mL RNAse A then stained
with 0.1mg/mL ethidium bromide. Each sample was then quantified using a C6
Flow Cytometer H System™ (BD Accuri™). The data was analyzed using CFlow
Plus software (BD Accuri™) and GraphPad Prism 6 (GraphPad Software Inc.)
(Summary of statistical analysis in Appendix G).
Results
Evaluation of the Physical Properties of PF13_0027
Initial evaluation of PF13_0027 included an investigation of potential
binding sites, phosphorylation sites, and post translational modifications. These
methods provided additional insight into potential interactions and function of this
putative phosphatase through the use of publicly available bioinformatics tools.
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Through the use of these tools, it was found that there were not any significant
phosphorylation sites or post translational modifications. PF13_0027 also did not
show presence of a signal peptide. The predicted secondary structure was used
to validate the homology model and supported the final structure.
Molecular Structure of PF13_0027
A crystallographic structure of PF13_0027 has not yet been resolved by
experimental methods and, neither is there a homologous protozoa protein that
could be used for a template. The closest template available in the Swiss Model
repository was the human phosphatase MKP3 with 21% similarity (Table 3.1 and
Figure 3.1). Analysis and validation of the structure using the WHAT-IF web
interface (version 8) revealed that the structure was in agreement with standard
structural conditions. Analysis of the Ramachandran plot gave a Z-score of 2.972 that was within the expected ranges for well-refined structures with 89.2%
of the amino acid residues in favored regions (Figure 3.2). All bonds were in
agreement with standard bond lengths with a RMS Z-score of 0.669 and RMS
deviation of 0.015. The overall quality of the model predicted by ERRAT was
69.375 compared to 88.235 of the template which was favorable considering the
numerous INDELs in primary sequence (Figure 3.3). Additionally, the RMSD
score from DaliLite of Cα trace between 141 aligned residues of 1MKP and the
homology model of PF13_0027 DUSP was 0.5 Å with a Z-score of 26.7 and 21%
sequence identity (Figure 3.4). The combined results from these various
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analyses suggest that the homology model of PF13_0027 DUSP is reasonable
and reliable.
Active Site Prediction
The predicted binding pockets for PF13_0027 were identified and
validated using Qsite-Finder, Pocket Finder and CASTp. A total of 10 binding
pockets were found and compared to the active site of the template protein
(Figure 3.5). The analysis revealed that the identified pocket in the region of the
signature motif was highly conserved with the template active site as predicted
through multiple sequence alignments. Sequence identity of the catalytic site
was greater (78%) between the template and homology model than in any other
region. This comparison also suggests functional conservation between the
template and model. The residues within the binding pocket include the
signature motif residues of previously characterized active phosphatases. For
example, the residues C383, D345 and I398 of PF13_0027 align with the
conserved C293, D262 and R299 of MKP3. Conservation of the predicted site
in the homology model and the validated site in the template suggests that the
selected pocket was the most favorable for HTS (Figure 3.6).
Ligand Selection and Drug Susceptibility Assay
From the ChEMBL-NTD dataset, 10001 compounds were docked and
ranked according to glide score. These molecular inhibitors were previously
screened with P. falciparum 3D7 and have a minimum inhibitory potential of 80%
validated using LDH activity assays as an index of growth (GSK TCAMS
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Dataset) or erythrocyte-based proliferation assays (Novartis-GNF Malaria Box
Dataset) [269, 322]. The bioactive drug-like small molecules in the database all
adhere to the Lipinski rule-of-five and provide abstracted bioactivities [323].
Cytotoxicity against human hepatocytoma HepG2 cells was observed in 1982 of
the compounds tested at 10 µM [269]. These compounds were evaluated on the
basis of their quality of interaction represented by the GLIDE calculation.
Commercially available compounds were identified from the results and 7
compounds (Table 3.2) were obtained (390097; 7,8-Dihydroxy-2H-chromen-2one: 524725; 1-(4-Chlorophenyl)-5-oxo-3-pyrrolidinecarboxylic acid: 533073; 2((N-[(4-Fluorophenyl)(2-thienyl)methyl]glycyl)amino)-3-thiophenecarboxamide:
533730; 2-([N-(Diphenylmethyl)glycyl]amino)-3-thiophenecarboxamide: 525841;
3-[(E)-(1H-Benzimidazol-2-ylhydrazono)methyl]-2-chloro-7-methoxyquinoline:
579624; 2-[(2E)-2-(1,3-Benzodioxol-5-ylmethylene)hydrazino]-1H-benzimidazole:
585222; 2-[(2E)-2-(3,4-Dimethoxybenzylidene)hydrazino]-1H-benzimidazole).
Poses of each compound were resolved to show the interaction of each molecule
with the active site residues (Figures 3.7-13).
Growth assays were performed with NF54 parasites while under drug
pressure with the selected compounds in order to evaluate and contrast the drug
attenuated phenotype to the insertional mutant phenotype observed with C9
(Figure 3.14-20). Since each of the selected compounds had published activity
against P. falciparum, it was expected that the parasites would be attenuated
over the course of the assay [269, 322]. The attenuated phenotype of C9, as
stated previously, presents a prolonged pre-S phase contributing to late entry
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into S/M development and a fold decrease in parasitemia 50% of the wild type.
As a starting point, the EC50 drug concentration of each of the selected inhibitory
compounds was used to challenge the parasites over the course of the
experiment. To assess the cell cycle phenotype, the relative abundance of each
developmental stage was quantified at each time point and plotted using a sixorder polynomial standard curve in order to visualize the function of the
developmental cycle. Overlaying the developmental stage growth curves for
each parasite culture enabled us to determine the course and timing of the cell
cycle. The initial published dose response assessment of each compound was
determined over the course of a 72 hour assay [269]. However, to develop a
clearer picture of the effect on the cell cycle, it was necessary to observe the
course of parasite development over two consecutive cycles. Therefore,
parasites in this study were cultured and monitored under drug pressure for 96
hours. Due to the extended length of the assay, it was possible to observe
attenuation greater than 50% in most treated cultures. Each compound
successfully attenuated pre-S development greater than 30 hours as in the C9
mutant extending the overall cycle time beyond that of the wild-type (Table 3.3).
Using Kruskal-Wallis multiple comparison with the Dunn’s post-test, we
determined that pre-S attenuation was similar to that of the C9 mutant (=0.05).
In addition to the pre-S phase, the overall timing of the development cycle was
compared and tested using the same statistical test (=0.05) (Table 3.4). Both
cycle time and pre-S phase timing are summarized in figure 3.20. Each drug
treated culture also showed a strong similarity to C9 in cycle timing.
80

To evaluate the effects of each of the inhibitors on cultures without the
proposed target, we set up dose-response assays with both NF54 and C9 to
compare the efficacy of the compounds in both parasite lines. In vitro drug
susceptibility assays also revealed that C9 had reduced susceptibility to 533073,
533730 and 579624 when compared with NF54 (Table 3.5).
Discussion
As an important regulatory process, phosphorylation cascades exert a
critical influence on cellular development through signal transduction, and as a
result, have been investigated extensively to elucidate methods of
chemotherapeutic intervention [224, 324-328]. These pathways have not yet
been fully characterized in Plasmodium, and as a result, there have not been any
classes of drugs developed to target phosphorylation-dependent signal
transduction cascades. Through preliminary characterizations of PF13_0027 in
the first part of this study, it was suggested that the pathway utilizing this putative
phosphatase may fulfill an important role in parasite development. Building on
these findings with homology modeling and in silico high-throughput screening,
our results support the idea that PF13_0027 might be suitable drug target. In the
past, computational methods have been successful in identifying potential
inhibitory compounds using critical components of the developmental cycle [329].
PF13_0027 presented as a critical component suitable for investigation through
computational methods. In P. falciparum, PF13_0027 is the only putative
phosphatase of its kind, and it is well conserved with single copy orthologs
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present in P. berghei (PBANKA_140400), P. c. chabaudi (PCHAS_140590), P.
knowlesi (PKH_140400), P. vivax (PVX_12110), P. cynomolgi (PCYB_141500),
and P. y. yoelii (PYYM_1407600). Additionally, PF13_0027 has low homology
with the closest mammalian orthologs. These characteristics are often indicators
of favorable drug targets since unique and conserved genes are typically under
negative selection making their products essential, and low homology to
mammalian genes limits adverse effects when targeted with drugs [10, 329].
Conservation among the Plasmodium parasites, especially P. falciparum
and P. vivax provides the ability to target both of these parasites, which would be
a great benefit to antimalarial drug discovery [31, 64]. The conserved binding
pocket of the homology modeled DUSP domain maintained the necessary
features for activity and demonstrated an ability to accommodate an inhibitor in
high-throughput in silico screening. Considering the structural characteristics, it
is likely that PF13_0027 interacts with the MAPK signaling pathway which is
critical and indispensable to eukaryote development, and it would be a major
contribution to the antimalarial research effort [143, 145, 157, 167, 201, 219, 330,
331].
The ChEMBL-NTD contains thousands of compounds with validated
antimalarial activity [269, 332, 333]. In light of their inhibitory actions, the targets
and mechanisms of action for most of them in P. falciparum are yet to be
determined. Hypothetical malarial modes of action were developed for a few
compounds to help facilitate their application against Plasmodium through
historical GSK data regarding biochemical activity with human and microbial
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targets [269]. In those previous studies, possible targets were inferred.
Unfortunately, none of the hypothetical targets were associated with the
compounds identified through the in silico screen in this current study. This
computational study, however, enabled us to sort through the database to isolate
the likely inhibitory compounds and allow us to correlate the proposed binding
interaction to a phenotype of an attenuated parasite line.
In order to determine if our protein of interest was being targeted by the
identified inhibitory compounds, it was necessary to follow up the preliminary
characterization of PF13_0027 with in silico methods of analysis using the
homology modeled DUSP. Replicating the phenotype observed in C9 with
selected inhibitors would suggest a potential mechanism of action. Additionally,
comparing the susceptibility of NF54 and C9 would give further insight into the
potential targeting of PF13_0027. This method would help facilitate lead
identification and optimization progressing toward structure-based drug
discovery. Though further studies would be required to determine the precise
inhibitory mechanism, this study demonstrates a novel translational method
bridging the gap between insertional mutagenesis and drug discovery. In vitro
attenuated growth analysis led to replication of the attenuated mutant phenotype
with the identified compounds and revealed that 524725, 533073 and 533730
have lowered efficacy against C9 parasites compared to the wild-type, validating
this approach and enabling us to postulate a therapeutic target of this inhibitor.
In addition to replicating the phenotype, observation of increased NF54
susceptibility compared to C9 makes it possible to suggest PF13_0027 may be
83

involved in the drug response phenotype in the assay. One of the main
challenges to post genomic biology is translating a pathogen’s genome to new
drugs and combinatorial methods with HTS allow us to identify suitable lead
candidates from a chemical database contributing to drug development efforts
and accelerating structure based design. In practice, experimentally determined
structures are preferred for in silico studies; however the number of
pharmaceutical targets of interest has far outpaced the ability to experimentally
develop protein structures [274]. As a result, homology modeling has become
the popular method of investigation for the growing number of interesting
pharmaceutical targets. Comparisons of docking results from both homology
models and experimentally validated structures have also produced comparable
results [181, 334].

Utilization of multiple strategies is necessary in order to

advance the base of knowledge in this field. In this dissertation research study,
we proposed a method to translate the information obtained from random
insertional mutagenesis into a drug discovery strategy using in silico methods.
The technique employs both experimental and computational methods to identify
drug compounds, which would be vital to the search for new antimalarials.
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Table 3.1: Templates identified for homology modeling.
Chain

Z

rmsd

lali

nres

%id

Description

1mkp-A

26.7

0.5

141

144

21

MKP3/ PYST1

3lj8-A

20.5

1.8

140

146

24

Tyrosine-protein Phosphatase

2hxp-A

18.1

2.1

136

144

21

DUSP 9

1zzw-B

17.9

2.1

134

147

21

DUSP10
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Figure 3.1: Alignment of potential homology modeling templates. Potential
templates were identified in Swiss Model and aligned in JalView. The
regions of greatest identity are marked with green. Below, the alignment of
the sequences shows the conserved regions in both the primary and
secondary structure.

86

Figure 3.2: The quality of the model was validated by Ramachandran plot.
The homology model was found to have 89.2% of the residues in favorable
positions.
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Figure 3.3: Overall quality assessment of the model evaluated using
ERRAT. The comparison of the template crystal structure and homology
model. (A) PF13_0027 (B) MKP3
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I398

D345
C383

Figure 3.4: Homology model of PF13_0027. The structure of PF13_0027
(brown) was developed using the crystal structure of MKP3 as a template
(PDB 1MKP). Alignment of the model with MKP3 (green) revealed that the
final structure showed the catalytic residues aligned to the proposed
positions in the active site. The presence of the signature motif insertion
does not affect the shape of the active site and forms an alpha-helix
adjacent to the binding pocket without obstructing the site.
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Table 3.2: Selected ChEMBL-NTD compounds used for in vitro screening.
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Figure 3.5: Identified binding site of PF13_0027 in the DUSP domain. The
binding pocket (red mesh) aligned with the predicted active site identified
by homology alignments with the template and other phosphatases. The
presence of the signature motif insertion does not obstruct the binding site.
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Figure 3.6: Vacuum electrostatics of the PF13_0027 DUSP homology
model. The blue signifies slight positive charge while the red shows the
negatively charged regions of the domain. The slight positive charge of the
binding pocket (circled) shows that it would be favorable for binding of a
negatively charged phosphate group. The predicted surface charges of the
homology model help validate the quality of the structure for docking.
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390097
N389
Q343
I398
390097
C383
D345

Figure 3.7: Orientation of 390097 in the binding pocket with LIGPLOT.
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524725
I398

Q343

C383
52472
5

D345

Figure 3.8: Orientation of 524725 in the binding pocket with LIGPLOT.
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533073

C383

D345
K394

I398

533073

Q343

Figure 3.9: Orientation of 533073 in the binding pocket with LIGPLOT.
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533730

C383

D345

N389

K394

I398
Q343

533730

Figure 3.10: Orientation of 533730 in the binding pocket with LIGPLOT.
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525841

I398
C383
525841

D345

N389

Figure 3.11: Orientation of 525841 in the binding pocket with LIGPLOT.
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579624

C383
I398

579624

D345

N389

Figure 3.12: Orientation of 579624 in the binding pocket with LIGPLOT.
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585222
C383
I398

D345

585222

N389

Figure 3.13: Orientation of 585222 in the binding pocket with LIGPLOT.
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Figure 3.14: NF54 parasites challenged with compound 390097. The plots
represent the asexual growth cycle of parasites treated with compound
390097 and the comparison to untreated NF54 and C9. The cycle was
determined by overlaying the relative abundance of rings (blue),
trophozoites (red) and schizonts (green).
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Figure 3.15: NF54 parasites were challenged with compound 524725. The
plots represent the asexual growth cycle of parasites treated with
compound 524725 and the comparison to untreated NF54 and C9. The
cycle was determined by overlaying the relative abundance of rings (blue),
trophozoites (red) and schizonts (green).
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Figure 3.16: NF54 parasites were challenged with compound 533073. The
plots represent the asexual growth cycle of parasites treated with
compound 533073 and the comparison to untreated NF54 and C9. The
cycle was determined by overlaying the relative abundance of rings (blue),
trophozoites (red) and schizonts (green).
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Figure 3.17: NF54 parasites were challenged with compound 533730. The
plots represent the asexual growth cycle of parasites treated with
compound 533730 and the comparison to untreated NF54 and C9. The
cycle was determined by overlaying the relative abundance of rings (blue),
trophozoites (red) and schizonts (green).
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Figure 3.18: NF54 parasites were challenged with compound 525841. The
plots represent the asexual growth cycle of parasites treated with
compound 525841 and the comparison to untreated NF54 and C9. The
cycle was determined by overlaying the relative abundance of rings (blue),
trophozoites (red) and schizonts (green).
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Figure 3.19: NF54 parasites were challenged with compound 579624. The
plots represent the asexual growth cycle of parasites treated with
compound 579624 and the comparison to untreated NF54 and C9. The
cycle was determined by overlaying the relative abundance of rings (blue),
trophozoites (red) and schizonts (green).
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Figure 3.20: NF54 parasites were challenged with compound 585222. The
plots represent the asexual growth cycle of parasites treated with
compound 585222 and the comparison to untreated NF54 and C9. The
cycle was determined by overlaying the relative abundance of rings (blue),
trophozoites (red) and schizonts (green).
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Table 3.3: Comparison of average pre-S phase times in treated cultures to
NF54 and C9. P-values represent comparison of each sample to C9.
Sample
390097
524725
533073
533730
525841
579624
585222
NF54
C9

Pre-S (hrs)
34.332.08
34.674.16
35.335.77
30.671.15
34.676.49
35.001.73
34.002.00
26.671.15
36.004.00
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p-value
0.676
0.734
0.676
0.071
0.480
0.979
0.638
0.008
-

Table 3.4: Comparison of average cycle times in treated cultures to NF54
and C9. P-values represent comparison of each sample to C9.
Sample
390097
524725
533073
533730
525841
579624
585222
NF54
C9

Cycle (hrs)
58.672.30
49.331.15
55.001.00
53.333.05
58.003.46
47.335.03
59.337.02
47.331.15
56.331.52
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p-value
0.338
0.147
0.959
0.698
0.484
0.097
0.484
0.052
-

70.00

60.00

Hours

50.00
40.00

Pre-S

30.00

Cycle

20.00
10.00

0.00

Figure 3.21: Comparison of cycle times and pre-S phase for treated and
untreated cultures.
The blue bars represent the pre-S phase of
development. Attenuated development is represented by a longer pre-S
phase compared to NF54. Each treated culture and C9 show an extended
pre-S phase. The total cycle time is represented by the red bars in each
sample.
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Table 3.5: Comparison of NF54 and C9 susceptibility to the selected
compounds. Compounds 5333073, 533730 and 579624 also show NF54 to
have significantly greater susceptibility.
Compound ID

EC50 NF54 (nM)

EC50 C9 (nM)

P-value

390097

340.253.6

248.933.7

0.1124

524725

503.136.5

248.462

0.0240

533073

471.937.4

1227.386.3

0.0013

533730

196.3113.8

510.951.6

0.0073

525841

186.133.8

224.748.1

0.5467

579624

13633.1

58439.86

0.0010

585222

378.897.7

339.328

0.7070
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Chapter 4: Conclusions and Future Directions
The studies described in this dissertation provide novel insights into a
putative phosphatase of P. falciparum. The presented data not only provides an
understanding of basic parasite biology, but provides a foundation for new
methods to reduce malaria transmission. Similar to the strategies utilized to
target signaling pathways in cancer research, the manipulation of signaling
pathways in Plasmodium can potentially support the development of
antimalarials capable of attenuating parasite development. The major findings of
this dissertation are that PF13_0027 is critical for development of the P.
falciparum trophozoite, and can be targeted for drug discovery. My results also
demonstrate that molecular modeling and in silico HTS can be used to translate
discoveries of critical genes identified through transposon-mediated random
insertional mutagenesis with pB into discoveries of new classes of antimalarial
drugs.
The first part of this dissertation focuses on an attenuated parasite line
(C9) that has an insertional knockout of PF13_0027 and investigates the
phenotype to determine the functional role. My data demonstrates that this gene
is important for pre-S development of the asexual trophozoite and that insertional
knockout attenuates blood stage cycling by delaying entry into the S/M schizont.
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Through complementation using the ORF with the 700 bp 5’ UTR promoter
region, the WT phenotype can be rescued, validating the critical nature of
PF13_0027 to development. Structural assessment of the domain architecture
and conserved regions reveals that not only does PF13_0027 have MKP
homology, but that it is missing a conserved residue in the signature motif, a
characteristic that is also common in STYX domains. The unique characteristics
in this putative phosphatase support that it could be a pseudophosphatase that
modulates the activity of the MAPK pathway through a dominant-negative
approach, or a low activity phosphatase.
The second part of this dissertation investigates the potential of targeting
PF13_0027 for drug discovery through in silico HTS using a homology model of
the DUSP domain. Using this procedure we attempted to chemically reproduce
the attenuated phenotype observed in C9 using molecular inhibitors from
ChEMBL-NTD. This procedure utilized the combined data sets of GSK-TCAMS,
Novartis-GNF malaria box and St. Jude Children’s Research hospital datasets.
Assessment of the attenuated phenotype of parasites treated with each of the
inhibitors reveals that the cell cycle of NF54 parasites is attenuated similar to that
of C9 when treated with the selected compounds suggesting that an inhibitor
identified through in silico methods could be used to replicate the attenuated
phenotype in vitro. This conclusion is important since this experiment, as a
proof-of-concept, shows that in silico methods may be used to rapidly sort and
translate the large library of data developed through large-scale insertion
mutagenesis into advanced insights in drug discovery. It also allows us to sort
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through large databases of small molecules to find valuable structures for future
structure-based drug design.
Taken together, the data presented in this dissertation show that
PF13_0027 is a very important component in asexual development and
proliferation. It also provides new insight into the importance of MAPK signaling
cascades to Plasmodium development. Future studies will focus on identification
of downstream signaling pathways and potential substrates. Additionally in depth
proteomic studies involving structural characterization, recombinant expression,
and functional in vitro assays will be able to generate a more specific
understanding of interacting substrates and the effects of potential inhibitors.
Current advancements in molecular and computational biology techniques
enable accurate representations of molecular interactions between potential drug
targets and molecular inhibitors. This study demonstrates that these methods
will augment current efforts expanding our knowledge of parasite biology and
help identify new drugs.
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Appendix A: Transfection Plasmids

Figure AI: The helper plasmid codes for the piggyBac transposase used in
random insertional mutagenesis. This helper plasmid was used in both the
initial transfection that knocked out PF13_0027 and in the complementation
experiments.
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Appendix A: continued

Figure AII: Plasmid used for the initial transfection knocking out PF13_0027.
The region between the ITRs was randomly inserted into the N-terminal
region of PF13_0027.
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Appendix A: continued

PF13_0027

pL-BACII-HBH
PF13_0027

Figure AIII: Plasmid used for complementation of C9. Complementation of
C9 with PF13_0027 required this construct with the N-terminal intergenic
promoter region (above schematic) and 3’CAM termination sequence. To
differentiate transfected clones a BSD selection marker was used in this
second round of transfection.
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Appendix B: Primers
Table BI: Primer list
Gene
PCR

Primers

PF13_0027

5′-CACCCTACCCCTGTATTATTTCCTACCCTC-3
5′-GTTTATGTAATTATTTATTACTATAAATGGTC-3

BSD

5′-GCCCTCCCACACATAACCAGAGGGCA-3′
5′-GCCTTTGTCTCAAGAAGAATCCACCCT-3′

hDHFR

5′-ATGGTTGGTTCGCTAAACTG-3′
5′-TTAATCATTCTTCTCATATACTTCAAA-3′

Episome

5′-AGATGTCCTAAATGCACAGCGAC-3′
5′-CAGGAAACAGCTATGAC-3′

RT-PCR
PF13_0027

5′-CACCATGGAATATAAAAGCATCGATTTTG-3′
5′-GTTTATGTAATTATTTATTACTATAAATGGTC-3′

18S RNA

5′-AACCTGGTTGATCTTGCCA-3′
5′-GTATTGTTATTTCTTGTCACTACCTCTC-3′

qRT-PCR
PF13_0027

5′-TCGATTTTGAGGAGCTGAA-3′
5′-GGGTAAAACATCCTTTTTGTT-3′

Southern Blot
Probe

5′-ATAAGAAGAAGTATATAATGAATTATATATAATGCT-3′
5′-CATATGTATTTTTTTTGTAATTTCTGTGTTTAT-3′

Site-directed Mutagenesis
D345A

5′-CTTTATGTACAAACCAAGTAAAAGCTAATAATACATCATTTATAAAAC-3′
5′-GTTTTATAAATGATGTATTATTAGCTTTTACTTGGTTTGTACATAAAG-3′

C383A

5′-CAAAATAATATCCTTATTATAGCTAATCATGGAATGAAAAATCCTAC-3′
5′-GTAGGATTTTTCATTCCATGATTAGCTATAATAAGGATATTATTTTG-3′

K388A/
K394A

5′-GTAATCATGGAATGGCAAATCCTACATCAGAAGCAACAAATAGTATAAGTC-3′
5′-GACTTATACTATTTGTTGCTTCTGATGTAGGATTTGCCATTCCATGATTAC-3′

154

Appendix C: Flow Cytometry Gating

Schizonts

Trophozoites

Uninfected cells

Rings
Figure CI: Gating used to sort the different developmental stages of asexual
P. falciparum cultures by flow cytometry. Ring stages with a lower DNA
content fluoresce at a lower wavelength in both the FL1-A and FL3-A
channels when stained with ethidium bromide, compared to the later stages.
Throughout development, as the parasites mature the wavelength of light
fluorescing off the infected cells in both channels increases. By using tightly
synchronized cultures, we are able to determine the precise pattern and
format the gate accordingly to sort different developmental stages. The
relative abundance of each developmental stage is then measured and
plotted. Overlaying these plots give us a graph that compared the relative
abundances and allows us to determine the cell cycle timing and
progression.
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Appendix D: Whole genome sequencing.
Table DI: Transposon insertions and SNPs in the genomes of NF54, C9 and
the complemented parasite lines. A single SNP in the putative clathrin coat
assembly protein AP180 was present in all samples. This experiment also
validated that the complementation of C9 was episomal
Clone Chromosome Position pB

Gene

Epi SNP

SNP gene

NF54

-

-

N

N

N

1

PFIT_1246000

C9

13

271811

Y

PF13_0027

N

1

PFIT_1246000

E3

13

271811

Y

PF13_0027

Y

1

PFIT_1246000

E8

13

271811

Y

PF13_0027

Y

1

PFIT_1246000
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Appendix E: Southern Blot of complemented parasites

Figure EI: Southern blot analysis of the transfected clones. Using a probe
specific to the BSD selection cassette produced signals representative of the
complementation plasmid (arrows).
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Appendix F: PCR Validation of complemented clones

Figure FI: PCRs used to validate the complemented parasite clones. The
hDHFR sequence (567 bp) is only present in the parasites that carried the
original transposon used to knock out PF13_0027 and was present in all
sequences except NF54. The BSD sequence (393 bp) was present in only
the positive transfectants and was not present in C9 or NF54. The third
reaction was used to test for the presence of the intact complementation
plasmid as an indication of episomal retention (608 bp) and was present in
all the clones. The fourth reaction used the Southern blot probe (711 bp) as
an additional validation that the selected clones carried the complementation
plasmid.
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Appendix G: Statistical Analysis Tables
Table GI: Growth assay analysis for NF54, C9, E3 and E8
Kruskal-Wallis test
P value
Do the medians vary signif. (P < 0.05)
Number of groups
Kruskal-Wallis statistic

Number of families
Number of comparisons
per family
Alpha

0.0038
Yes
4
13.44

1
6
0.05

Dunn's multiple
comparisons test

Significant?

NF54 vs. C9
NF54 vs. E3
NF54 vs. E8
C9 vs. E3
C9 vs. E8
E3 vs. E8

Yes
No
No
Yes
Yes
No
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Appendix G: continued
Table GII: Invasion assay analysis for NF54, C9, E3 and E8

Kruskal-Wallis test
P value
Do the medians vary signif. (P < 0.05)
Number of groups
Kruskal-Wallis statistic

Number of families
Number of comparisons
per family
Alpha

0.0152
Yes
4
8.128

1
6
0.05

Dunn's multiple
comparisons test

Significant?

C9 vs. E3
C9 vs. E8
C9 vs. NF54
E3 vs. E8
E3 vs. NF54
E8 vs. NF54

Yes
Yes
Yes
No
No
No
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Appendix G: continued
Table GIII: Growth assay analysis for NF54, C9, D345A, C383A, and
K388A/ K394A

Kruskal-Wallis test
P value
Exact or approximate P value?
Do the medians vary signif. (P < 0.05)
Number of groups
Kruskal-Wallis statistic

0.0031

Exact
Yes
5
11.05

Number of families
Number of comparisons per family
Alpha

1
10
0.05

Dunn's multiple comparisons test

Significant?

NF54 vs. C9
NF54 vs. C383A
NF54 vs. D345A
NF54 vs. K388A K394A
C9 vs. C383A
C9 vs. D345A
C9 vs. K388A K394A
C383A vs. D345A
C383A vs. K388A K394A
D345A vs. K388A K394A

Yes
Yes
Yes
No
No
No
Yes
No
Yes
Yes
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Appendix G: continued
Table GIV: Invasion assay analysis for NF54, C9, D345A, C383A, and
K388A/ K394A

Kruskal-Wallis test
P value
Exact or approximate P value?
Do the medians vary signif. (P < 0.05)
Number of groups
Kruskal-Wallis statistic

0.0003

Exact
Yes
5
12.23

Number of families
Number of comparisons per family
Alpha

1
10
0.05

Dunn's multiple comparisons test

Significant?

NF54 vs. C9
NF54 vs. C383A
NF54 vs. D345A
NF54 vs. K388A K394A
C9 vs. C383A
C9 vs. D345A
C9 vs. K388A K394A
C383A vs. D345A
C383A vs. K388A K394A
D345A vs. K388A K394A

Yes
Yes
Yes
No
No
No
Yes
No
Yes
Yes
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Appendix H: Bioinformatics
Table HI: Bioinformatics Resources
Tool

Version

URL

Databases
PlasmoDB

9.2

http://plasmodb.org/plasmo/

GenBank

194

http://www.ncbi.nlm.nih.gov/genbank/

ChEMBL-NTD
Prosite
Superfamily

https://www.ebi.ac.uk/chemblntd
20.89
1.75

http://prosite.expasy.org/
http://supfam.cs.bris.ac.uk/SUPERFAMILY/

Prediction and Characterization
ProtParam

http://web.expasy.org/protparam/

CDD

http://www.ncbi.nlm.nih.gov/cdd/

CDART

http://www.ncbi.nlm.nih.gov/Structure/lexington/lexington.cgi

InterProScan
SMART

4.8
7

NCBI BLASTP
JPRED
PSIPRED

http://www.ebi.ac.uk/Tools/pfa/iprscan/
http://smart.embl-heidelberg.de/
http://blast.ncbi.nlm.nih.gov/Blast.cgi

3
3.2

http://www.compbio.dundee.ac.uk/www-jpred/
http://bioinf.cs.ucl.ac.uk/psipred/

Net Phos 2.0

2

http://www.cbs.dtu.dk/services/NetPhos/

Net PhosK 1.0

1

http://www.cbs.dtu.dk/services/NetPhosK/

Predotar

1.03

http://urgi.versailles.inra.fr/predotar/predotar.html

PATS

1.2.1

http://gecco.org.chemie.uni-frankfurt.de/pats/pats-index.php

Modeling
Swiss-Model

http://swissmodel.expasy.org/

Structure Validation
ANOLEA

http://protein.bio.puc.cl/anolea/index.html

GROMOS

http://www.gromacs.org/Documentation/Terminology/Force_Fields/GROMOS

QMEAN6

http://swissmodel.expasy.org/qmean/cgi/index.cgi

PROCHECK

http://www.ebi.ac.uk/thornton-srv/software/PROCHECK/

DSSP

2

http://swift.cmbi.ru.nl/gv/dssp/

PROMOTIF

3

http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=n/a&t

ERRAT

2

http://nihserver.mbi.ucla.edu/ERRATv2/

Verify3D

http://nihserver.mbi.ucla.edu/Verify_3D/

RAMPAGE

http://mordred.bioc.cam.ac.uk/~rapper/rampage.php

Pocket Finder

http://www.modelling.leeds.ac.uk/pocketfinder/help.html

Q-Site Finder

http://www.modelling.leeds.ac.uk/qsitefinder/

CASTp

http://sts.bioengr.uic.edu/castp/calculation.php

WHAT-IF

8

http://swift.cmbi.ru.nl/whatif/
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Appendix I: Content Permissions
Malaria life cycle:
 Content Providers: CDC/Alexander J. da Silva, Ph.D/ Melanie Moser
 Permission: PD-USGov-HHS-CDC
 This image is in the public domain and thus free of any copyright
restrictions. As a matter of courtesy we request that the content
provider be credited and notified in any public or private usage of the
image.
 http://www.dpd.cdc.gov/dpdx/images/ParasiteImages/MR/Malaria/malaria_LifeCycle.gif
Maps
 Malaria Atlas Project
 Creative Commons Attribution 3.0 Unported (CC by 3.0)
 Free to share (copy, distribute and transmit the work); remix (adapt
the work); make commercial use of the work.
http://creativecommons.org/licenses/by/3.0/
 http://www.map.ox.ac.uk/
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